[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 372
1. Denève E, Ramos J, Aufort S, Marchand JP, Rousset T, Perrochia H, Domergue J, Navarro F: [Endocrine tumor arising in heterotopic gastric pancreas]. Gastroenterol Clin Biol; 2008 Feb;32(2):195-201
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumor arising in heterotopic gastric pancreas].
  • [Transliterated title] Tumeur endocrine développée sur pancréas ectopique gastrique.
  • We report the case of a 49-year-old caucasian woman, in whom an endocrine tumor arising in gastric heterotopic pancreas was diagnosed.
  • Heterotopic pancreas is a benign anatomic condition, probably widely underdiagnosed because usually asymptomatic.
  • The endocrine tumors developed in heterotopic pancreas are exceedingly rare.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Choristoma / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387430.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gastrins; 51110-01-1 / Somatostatin
  •  go-up   go-down


2. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V: Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol; 2009 Jul;22(7):933-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.
  • Pancreatic endocrine tumors are rare tumors with unpredictable clinical behavior.
  • No histological features or immunohistochemical markers reliably predict malignant progression and the molecular basis of progression of pancreatic endocrine tumors remains unknown.
  • The metastasis-associated gene 1 is thought to play a role in transcription repression and estrogen receptor interaction and is overexpressed in several human cancers, including endocrine neoplasms.
  • The purpose of this study was to analyze the expression of metastasis-associated gene 1 in pancreatic endocrine tumors for its possible role in malignant progression.
  • Twenty-seven pancreatic endocrine tumors were identified from our archive.
  • The clinical follow-up data were examined and tumors were classified according to the 2004 World Health Organization criteria as benign behavior (WHO 1.1), uncertain behavior (WHO 1.2), well-differentiated endocrine carcinoma (WHO 2), and poorly differentiated endocrine carcinoma (WHO 3).
  • Metastasis-associated gene 1 expression was significantly higher in malignant tumors (n=17) with a mean staining intensity of 3.8 compared with 2.9 in benign tumors (n=10, P=0.046).
  • The expression levels were significantly associated with WHO class (P=0.028), as well as size of tumor (P=0.029), and mitotic rate (P=0.035).
  • We show that metastasis-associated gene 1 expression is significantly associated with malignant behavior in pancreatic endocrine tumors.
  • This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell / enzymology. Carcinoma, Islet Cell / enzymology. Histone Deacetylases / metabolism. Islets of Langerhans / enzymology. Pancreatic Neoplasms / enzymology. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377441.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


3. Marcelino M, Nobre E, Conceição J, Lopes L, Vilar H, França Martins M, Carvalho A, André S, Horta A, De Castro JJ: [A rare case of hyperandrogenism: bilateral Leydig cell tumor of the ovary]. Acta Med Port; 2010 Jan-Feb;23(1):113-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of hyperandrogenism: bilateral Leydig cell tumor of the ovary].
  • [Transliterated title] Um caso raro de hiperandrogenismo tumor ovárico bilateral de células de Leydig.
  • Leydig cell tumor is one of the most common of this type of lesion and it is usually benign, small and unilateral.
  • CASE REPORT: A 67 year old woman was referred to the Endocrine clinic due to hirsutism (score 22 Ferriman-Gallwey) and male type alopecia with 3 years of evolution and progressive worsening.
  • In this case report we present a rare case of bilateral Leydig cell tumor.
  • Only five cases have been reported in the literature.The clinical history and the elevated levels of testosterone had suggested the presence of an androgen-producing tumor, despite the difficulty of the diagnosis on imaging techniques.
  • The histopathologic disclosed the diagnosis and allowed the patient's cure.
  • [MeSH-major] Hirsutism / etiology. Leydig Cell Tumor / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353714.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


Advertisement
4. Hsieh MS, Liu KL, Tien YW, Shun CT: Combined pancreatic endocrine tumor and serous cystadenoma. J Formos Med Assoc; 2009 Sep;108(9):739-45
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined pancreatic endocrine tumor and serous cystadenoma.
  • Pancreatic serous cystadenomas account for 1-2% of all exocrine pancreatic tumors, and endocrine tumors account for 1-2% of all pancreatic neoplasms.
  • The combination of pancreatic serous cystadenoma and endocrine tumor is even rarer.
  • Here, we report two cases of combined pancreatic serous adenoma and endocrine tumor.
  • One was a 64-year-old woman with serous cystadenoma and pancreatic endocrine tumor.
  • The other case was a 28-year-old woman with von Hippel-Lindau disease with combined pancreatic serous oligocystic adenoma and well-differentiated malignant endocrine carcinoma.
  • Careful examination of benign serous cystadenoma should be kept in mind during clinical practice, to rule out the possibility of combined malignant endocrine tumor.
  • In addition, von Hippel-Lindau disease should also be suspected when a young adult presents with combination of pancreatic serous cystadenoma and endocrine tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773214.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 15
  •  go-up   go-down


5. Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer; 2007 Mar;14(1):13-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical cancer (ACC) is a rare tumor with a poor prognosis.
  • By contrast, benign adrenocortical tumors are frequent, underlying the importance of a correct diagnosis of malignancy of such tumors.
  • ACC can be diagnosed by the investigation of endocrine signs of steroid excess, symptoms due to tumor growth or an adrenal incidentaloma.
  • Imaging by CT-scan or MRI shows a large heterogeneous tumor with a low fat content.
  • Careful pathological investigation with the assessment of the Weiss score is important for the diagnosis of malignancy.
  • Tumors localized to the adrenal gland (McFarlane stages 1 and 2) have a better outcome than invasive and metastatic tumors (stages 3 and 4).
  • Tumor removal by a specialized team is crucial for treatment and should always aim at complete removal.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / therapy
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Oncogenes / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395972.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 127
  •  go-up   go-down


6. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stålberg P, Khanafshar E, Shibru D, Duh QY, Clark OH, Kebebew E, Gill AJ, Clifton-Bligh R, Robinson BG, Benn DE, Sidhu SB: MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer; 2010 Sep;17(3):835-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
  • There is increasing evidence to suggest that miRNAs could be useful in cancer diagnosis, prognosis, and therapy.
  • We performed miRNA microarray expression profiling on a cohort of 12 benign and 12 malignant pheochromocytomas and identified a number of differentially expressed miRNAs.
  • These results were validated in a separate cohort of ten benign and ten malignant samples using real-time quantitative RT-PCR; benign samples had a minimum follow-up of at least 2 years.
  • It was found that IGF2 as well as its intronic miR-483-5p was over-expressed, while miR-15a and miR-16 were under-expressed in malignant tumours compared with benign tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. MicroRNAs / physiology. Pheochromocytoma / genetics
  • [MeSH-minor] Adrenal Glands / metabolism. Adrenal Glands / pathology. Animals. Apoptosis. Blotting, Western. Cell Cycle. Cohort Studies. Follow-Up Studies. Humans. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured


7. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


8. Ramuz O, Lelong B, Giovannini M, Delpero JR, Rochaix P, Xerri L, Hassoun J, Flejou JF, Monges G: "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies. Virchows Arch; 2005 May;446(5):555-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies.
  • This study is the second to report a pancreatic "sugar" tumor (ST) case.
  • This ST was incidentally discovered in a 31-year-old woman using computed tomography scan (CT scan) for work-up of a hepatic focal nodular hyperplasia.
  • Both CT scan and endoluminal ultrasonography (EUS) features evoked a 15-mm large benign endocrine tumor.
  • Pathological examination of EUS-guided fine-needle aspiration biopsies could not confirm this diagnosis.
  • The tumor was intrapancreatic, well circumscribed, and organized in sheets of epithelioid cells.
  • The tumor cells expressed HMB-45 but did not express epithelial or endocrine immunohistochemical markers.
  • This observation highlights that STs should be considered in preoperative differential diagnosis of pancreas tumors, since they may be treated by limited surgical resection.
  • [MeSH-major] Biopsy, Fine-Needle. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Angiomyolipoma / chemistry. Angiomyolipoma / pathology. Angiomyolipoma / surgery. Antigens, Neoplasm. Diagnosis, Differential. Female. Focal Nodular Hyperplasia / complications. Humans. Laparoscopy. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Pancreatectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1994 Jul;26(3):230-6 [7991275.001]
  • [Cites] Pathologe. 2001 Nov;22(6):417-23 [11766641.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):563-8 [11406657.001]
  • [Cites] Mod Pathol. 2003 May;16(5):481-90 [12748255.001]
  • [Cites] Arch Pathol Lab Med. 1988 Dec;112(12):1177-8 [3190399.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):517-9 [6733682.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):670-5 [11979098.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1239-46 [10976698.001]
  • [Cites] Hepatology. 1997 Oct;26(4):891-5 [9328310.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jun;125(6):751-8 [11371226.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):65-70 [11145253.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):121-6 [11145246.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):615-22 [11406665.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1063-7 [9781642.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):722-30 [8651352.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):889-94 [10843294.001]
  • [Cites] Pancreas. 2004 May;28(4):443-5 [15097863.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1295-9 [10976706.001]
  • (PMID = 15821930.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


9. Nodit L, McGrath KM, Zahid M, Jani N, Schoedel KE, Ohori NP, Carty S, Finkelstein S, Khalid A: Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome. Clin Gastroenterol Hepatol; 2006 Dec;4(12):1474-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome.
  • BACKGROUND & AIMS: The clinical course of pancreatic endocrine tumor (PET) varies depending on tumor aggressiveness, disease extent, and possibly accumulated molecular alterations.
  • Representative tumor cells were microdissected from the FNA material.
  • Thirteen were classified histologically as benign PET limited to the pancreas and 12 as malignant PET (invasive or metastatic).
  • The mean FAL in the benign and malignant PET was 0.03 and 0.37 (P<.0001), respectively.
  • [MeSH-major] DNA, Neoplasm / analysis. Endoscopy, Digestive System / methods. Loss of Heterozygosity / genetics. Microsatellite Repeats / genetics. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996803.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


10. Serra S, Asa SL, Bamberger AM, Wagener C, Chetty R: CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):286-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM1 expression in pancreatic endocrine tumors.
  • The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters.
  • Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis.
  • A tissue microarray was constructed and stained with an extensive panel of endocrine markers and CEACAM1.
  • Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease.
  • Benign tumors and PETs of uncertain malignant behavior were more frequently CEACAM1-negative and low-grade malignant cases were CEACAM1 positive (27 of 29 cases) (P=0.001).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349857.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  •  go-up   go-down


11. Callender GG, Rich TA, Perrier ND: Multiple endocrine neoplasia syndromes. Surg Clin North Am; 2008 Aug;88(4):863-95, viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia syndromes.
  • The multiple endocrine neoplasia (MEN) syndromes are rare autosomal-dominant conditions that predispose affected individuals to benign and malignant tumors of the pituitary, thyroid, parathyroids, adrenals, endocrine pancreas, paraganglia, or nonendocrine organs.
  • However, several other hereditary conditions should also be considered in the category of MEN: von Hippel-Lindau syndrome, the familial paraganglioma syndromes, Cowden syndrome, Carney complex, and hyperparathyroidism jaw-tumor syndrome.
  • In addition, researchers are becoming aware of other familial endocrine neoplasia syndromes with an unknown genetic basis that might also fall into the category of MEN.
  • This article reviews the clinical features, diagnosis, and surgical management of the various MEN syndromes and genetic risk assessment for patients presenting with one or more endocrine neoplasms.
  • [MeSH-major] Endocrine Surgical Procedures / methods. Genetic Predisposition to Disease. Genetic Testing / methods. Multiple Endocrine Neoplasia

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672144.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 110
  •  go-up   go-down


12. Kapran Y, Bauersfeld J, Anlauf M, Sipos B, Klöppel G: Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch; 2006 Apr;448(4):394-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multihormonality and entrapment of islets in pancreatic endocrine tumors.
  • We analyzed pancreatic endocrine tumors (PETs) from 200 patients for the incidence of multihormonality and entrapped islets and correlated the results with clinicopathological features.
  • Classified according to the WHO classification, there were 32 well-differentiated benign PETs, 85 well-differentiated PETs with uncertain behavior, and 83 well-differentiated malignant PETs.
  • Islet entrapment was found in 57 tumors (28.5%) and was significantly more frequent in PETs with uncertain and malignant behavior than benign ones (p=0.01).
  • We conclude that the incidence of multihormonality in PETs is not as high as suggested previously and islet entrapping may reflect aggressive tumor growth and may be a complementary criterion for predicting the biological behavior of PETs.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Islets of Langerhans / pathology. Pancreatic Hormones / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):191-8 [1317556.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1420-9 [2992737.001]
  • [Cites] Semin Diagn Pathol. 1984 Nov;1(4):285-96 [6100974.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):908-15 [6277456.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):813-20 [15166675.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):258-65 [12647216.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):461-8 [12657930.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1378-84 [8898842.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] Surg Today. 1992;22(4):305-12 [1392340.001]
  • [Cites] Histopathology. 1978 Nov;2(6):389-99 [215502.001]
  • [Cites] Am J Surg Pathol. 1982 Jul;6(5):387-99 [6127037.001]
  • [Cites] Histopathology. 2002 Aug;41(2):122-6 [12147089.001]
  • [Cites] Am J Pathol. 1975 May;79(2):271-84 [167586.001]
  • [Cites] Virchows Arch. 2003 May;442(5):444-52 [12692724.001]
  • (PMID = 16418841.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones
  •  go-up   go-down


13. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, Antonetti T, Luong TV, Rindi G: Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol; 2006;17(2):119-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for malignancy in gastrointestinal endocrine tumors.
  • In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract.
  • In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade.
  • In this review the differential tumor characteristics between the different categories are summarized.
  • Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
  • [MeSH-major] Endocrine Gland Neoplasms / classification. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Ki-67 Antigen. Mitotic Index. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159244.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 51
  •  go-up   go-down


14. Rindi G, Couvelard A, Scoazec JY, Bordi C: [Practical notes for the evaluation of malignancy in digestive endocrine tumors]. Ann Pathol; 2005 Dec;25(6):487-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical notes for the evaluation of malignancy in digestive endocrine tumors].
  • [Transliterated title] Evaluation de la malignité dans les tumeurs endocrines digestives: recommandations pratiques.
  • For a long time, the assessment of malignancy risk and patient outcome in digestive endocrine tumors had to rely on sparse and mostly unconfirmed data.
  • The 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded to be useful for clinical purposes, providing the basis for proper patient management and for designing treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • 1) well differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • 2) well differentiated endocrine carcinomas, low grade; and 3) poorly differentiated endocrine carcinomas, high grade.
  • In this review the differential tumor characteristics between the above categories are summarized.
  • The relevance of additional features as for tumor prognostication, chiefly the Ki67 proliferation index and malignancy associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and midgut origin.
  • [MeSH-major] Digestive System Neoplasms / pathology. Gastrointestinal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Pancreatic Neoplasms / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735974.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 47
  •  go-up   go-down


15. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C: A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab; 2010 May;95(5):2023-37
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma.
  • Results were narrowed to manuscripts that included children and studies related to the genetics of PHEO/PGL.
  • Most are functional tumors, and clinical presentation includes symptoms related to catecholamine hypersecretion and/or tumor mass effect.
  • Increasingly, PHEO/PGL are identified during presymptomatic screening in children with genetic syndromes associated with PHEO/PGL (multiple endocrine neoplasia type 2, von Hippel-Lindau disease, and the paraganglioma syndromes).
  • Plasma and/or urine metanephrines are the best diagnostic test for a functional tumor, and the management of pediatric patients is similar to adults.
  • Although most pediatric PHEO/PGL are benign, these tumors can occasionally metastasize, a condition for which no curative treatment exists.
  • CONCLUSIONS: Although PHEO/PGL are rarely diagnosed during childhood, the pediatric provider should be able to recognize and screen for such tumors, particularly in the context of a known genetic predisposition.
  • Optimal care of these children includes a multidisciplinary team approach at centers experienced in the evaluation and treatment of these uncommon yet fascinating endocrine neoplasms.
  • [MeSH-minor] Child. Dopamine / metabolism. Genetic Counseling. Humans. Mutation, Missense. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20215394.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; VTD58H1Z2X / Dopamine
  • [Number-of-references] 139
  •  go-up   go-down


16. Dallago CM, Oliveira MC, Barbosa-Coutinho LM, Ferreira NP: Angiogenesis in craniopharyngiomas: Microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin. Endocr Pathol; 2005;16(4):355-62
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are benign tumors of the sellar region generally associated with endocrine abnormality and often locally aggressive.
  • The microvascular density (MVD) of craniopharyngiomas was determined in tumor tissue samples from a reference neurosurgery center located in southern Brazil using immunohistochemical methods for two endothelial markers, CD34 and CD105 (endoglin).
  • There was no association between the two endothelial markers and tumor extension.
  • We were not able to establish a relationship between angiogenesis in craniopharyngiomas and tumor extension with the endothelial markers used in this study.
  • We believe that CD105 antigen can be a more specific endothelial marker for tumor angiogenesis than CD34 antigen.
  • [MeSH-major] Craniopharyngioma / blood supply. Endostatins / metabolism. Neovascularization, Pathologic / pathology. Pituitary Neoplasms / blood supply. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627922.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / ENG protein, human; 0 / Endostatins; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


17. Granberg D, Wilander E, Oberg K: Expression of tyrosine kinase receptors in lung carcinoids. Tumour Biol; 2006;27(3):153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Typical lung carcinoids are usually relatively benign tumors, but distant metastases are seen in up to 12% of the patients.
  • PATIENTS AND METHODS: Tumor tissue from 51 patients with typical lung carcinoids were immunostained with polyclonal antibodies against c-kit, PDGFRalpha, PDGFRbeta and EGFR.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Lung Neoplasms / diagnosis. Receptor Protein-Tyrosine Kinases / analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612146.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


18. Vezzosi D, Bouisson M, Escourrou G, Laurell H, Selves J, Seguin P, Pradayrol L, Caron P, Buscail L: Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours. Clin Endocrinol (Oxf); 2006 Jan;64(1):63-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours.
  • OBJECTIVE: The distinction between benign and malignant well-differentiated endocrine tumours is hard to achieve.
  • The aim of the present study was to determine whether detection of telomerase or quantification of human telomerase reverse transcriptase protein subunit (hTERT) differ between benign and malignant endocrine tumours.
  • PATIENTS AND METHODS: This retrospective study investigated 31 well-differentiated primary endocrine tumours.
  • Based on clinical and histopathological criteria, tumours were categorized with the most recent WHO classification as 'benign' (n = 14), 'uncertain' (n = 5) or 'malignant' (n = 12) with (n = 7) or without (n = 5) metastasis after a mean follow-up of 40.4 +/- 25.8 months (4-122 months).
  • RESULTS: Telomerase activity was detected in 7 malignant and metastatic tumours, in 1 malignant tumour without metastases, in 1 uncertain tumour and in 1 benign tumour. hTERT mRNA levels were significantly higher in malignant endocrine tumours with or without metastases (P = 0.001) when compared to benign tumours.
  • The negative predictive value of hTERT mRNA quantification for the diagnosis of malignancy was 88.9%, whereas the positive predictive value was 68.7%.
  • CONCLUSION: The presence of telomerase activity within the primary endocrine tumour might indicate a malignant tumour and might suggest the need for an attentive search for concomitant metastases.
  • Quantification of hTERT mRNA could be used in clinical practice to exclude malignancy in most endocrine tumours.
  • [MeSH-major] Biomarkers, Tumor / analysis. Clinical Enzyme Tests. DNA-Binding Proteins / analysis. Endocrine Gland Neoplasms / diagnosis. Telomerase / analysis
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Female. Gastrinoma / diagnosis. Glucagonoma / diagnosis. Humans. Insulinoma / diagnosis. Intestinal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Male. Middle Aged. Pancreatic Neoplasms / diagnosis. Pheochromocytoma / diagnosis. Predictive Value of Tests. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402930.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


19. van Nederveen FH, Korpershoek E, deLeeuw RJ, Verhofstad AA, Lenders JW, Dinjens WN, Lam WL, de Krijger RR: Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocr Relat Cancer; 2009 Jun;16(2):505-13
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-comparative genomic hybridization in sporadic benign pheochromocytomas.
  • Pheochromocytomas (PCC) are catecholamine-producing tumors arising from the adrenal medulla that occur either sporadically or in the context of hereditary cancer syndromes, such as multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease (VHL), neurofibromatosis type 1, and the PCC-paraganglioma syndrome.
  • Conventional comparative genomic hybridization studies have shown loss of 1p and 3q in the majority of sporadic and MEN2-related PCC, and 3p and 11p loss in VHL-related PCC.
  • The development of a submegabase tiling resolution array enabled us to perform a genome-wide high-resolution analysis of 36 sporadic benign PCC.
  • We conclude that there appear to be two subgroups of benign sporadic PCC, one of which has a pattern of chromosomal abnormalities that is comparable with PCC from patients with MEN2 and the other that is comparable with the PCC that arise in patients with VHL disease.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Oligonucleotide Array Sequence Analysis. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 3 / genetics. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a / genetics. Mutation / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153209.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


20. Gartner W, Mineva I, Daneva T, Baumgartner-Parzer S, Niederle B, Vierhapper H, Weissel M, Wagner L: A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet; 2005 Jul;117(2-3):143-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.
  • To investigate endocrine tumor tissue characteristic RET proto-oncogene expression, we performed quantitative RT-PCR, Northern blot and Southern blot analyses of benign and malignant endocrine-derived tissues.
  • In addition, the presence of a 3'-terminally truncated RET proto-oncogene mRNA variant in benign and malignant thyroid neoplasias, as well as in a pheochromocytoma, an ovarian carcinoma and a medullary thyroid carcinoma, is demonstrated.
  • This polymorphism is close to a recently described polyadenylation site and lies within a binding site for the nucleic acid binding protein Pbx-1.
  • Screening of healthy subjects and of patients suffering from various endocrine malignancies revealed exclusively allele 1 homozygous and allele 1/allele 2 heterozygous genotypes.
  • Heterozygous genotypes were found in a significantly higher percentage in samples derived from endocrine tumor patients when compared with those from healthy control subjects.
  • Homozygosity for allele 2 was found exclusively in somatic DNA derived from endocrine tumors with high malignant potential.
  • In conclusion, our data demonstrate presence of a 5'-terminal RET proto-oncogene transcript in endocrine tissues and reveal a bi-allelic RET proto-oncogene polymorphism.
  • A heterozygous genotype for this polymorphism is found in a considerable number of endocrine tumor patients.
  • [MeSH-major] 3' Untranslated Regions / genetics. Endocrine Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Loss of Heterozygosity / genetics. Oncogene Proteins / genetics. Polymorphism, Restriction Fragment Length. Receptor Protein-Tyrosine Kinases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1992;61:419-40 [1353951.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Dev Biol. 2003 Feb 15;254(2):262-76 [12591246.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):380-3 [8114940.001]
  • [Cites] Mol Cell Neurosci. 1999 May;13(5):313-25 [10356294.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2039-45 [7478523.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Pathol. 1994 Mar;172(3):255-60 [8195928.001]
  • [Cites] Nucleic Acids Res. 1996 Jun 15;24(12):2288-94 [8710498.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):785-9 [8657281.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1377-83 [7731689.001]
  • [Cites] Oncogene. 1999 Jul 1;18(26):3919-22 [10445857.001]
  • [Cites] J Mol Med (Berl). 2003 Jul;81(7):411-9 [12811413.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2845-9 [10850426.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):789-93 [8657282.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3445-8 [10918602.001]
  • [Cites] Oncogene. 1988 Nov;3(5):571-8 [3078962.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):430-5 [11912494.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):377-8 [8114938.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Jun 30;153(3):1290-5 [3390185.001]
  • [Cites] Hum Genet. 1995 Jul;96(1):27-32 [7607650.001]
  • [Cites] Nucleic Acids Res. 1990 Dec 25;18(24):7472 [1979682.001]
  • [Cites] Oncogene. 1990 Jan;5(1):97-102 [2181380.001]
  • [Cites] Biochimie. 1999 Apr;81(4):397-402 [10401675.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1369-73 [10022819.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2575-82 [8361767.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):168-86 [12652644.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):380-93 [10458257.001]
  • [Cites] Cell. 1985 Jun;41(2):349-59 [2580642.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1025-32 [12963982.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1595-8 [1701232.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • (PMID = 15841388.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


21. Ledinsky M, Coc I, Stancić V, Borić M, Tomas D: Pancreatic endocrine tumor of uncertain behavior: a case report. Acta Clin Croat; 2008 Sep;47(3):165-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor of uncertain behavior: a case report.
  • Pancreatic endocrine tumors are rare, and among them large non-functioning tumors of uncertain behavior are extremely infrequent.
  • Non-functioning pancreatic endocrine tumors originate from the endocrine part of the pancreas but are not associated with a distinct hormonal syndrome.
  • A rare case is presented of a 49-year-old woman with a well-differentiated endocrine tumor of uncertain behavior that presented with intermittent pain in the epigastrium radiating to the right subcostal region.
  • Microscopically, the tumor had relatively uniform cells with oval nuclei that coated trabecular and pseudoglandular structures, which also showed 1 mitosis per 10 VVP and proliferation activity measured with Ki67 of less than 2%.
  • Immunohistochemical analyses for NSE, chromogranin and synapthophysin were positive, which along with its size (over 2 cm in diameter) and reported angioinvasion indicated the diagnosis of pancreatic endocrine tumor of uncertain behavior.
  • Although mostly considered as malignant, large non-functioning pancreatic endocrine tumors can sometimes express benign or uncertain behavior; therefore, a large number of factors should always be considered when determining the biological nature of these tumors.
  • [MeSH-major] Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175066.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


22. Simon P, Spilcke-Liss E, Wallaschofski H: Endocrine tumors of the pancreas. Endocrinol Metab Clin North Am; 2006 Jun;35(2):431-47, xii
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumors of the pancreas.
  • Neuroendocrine tumors of the pancreas are rare neoplasms of the heterogeneous group of neuroendocrine gastroenteropancreatic tumors that originate from totipotential stem cells or preexisting endocrine cells within the pancreas.
  • Most neuroendocrine tumors of the pancreas are benign or show an indolent course of disease.A subset of them shows a very aggressive behavior, becomes highly malignant, and metastasizes early with life-limiting consequences.
  • An effective disease-management includes the diagnostic approach with hormonal testing and localization and surgical treatment with histologic classification in combination with biotherapy, chemotherapy, or therapy with radionucleotides, de-pending on the individual behavior of the tumor.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Diagnostic Imaging. Drug Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632104.001).
  • [ISSN] 0889-8529
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


23. Tömböl Z, Eder K, Kovács A, Szabó PM, Kulka J, Likó I, Zalatnai A, Rácz G, Tóth M, Patócs A, Falus A, Rácz K, Igaz P: MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol; 2010 Dec;23(12):1583-95
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas.
  • The objective of our study was to perform microRNA expression profiling in sporadic and hereditary benign, and recurring adrenomedullary tumors.
  • A total of 21 formalin-fixed paraffin-embedded samples (sporadic benign, multiple endocrine neoplasia 2, von Hippel-Lindau disease, sporadic recurring) were subjected to microRNA expression profiling using microarrays.
  • Furthermore, microRNA expression profiles of a malignant pheochromocytoma and a pair of primary and recurrent tumors were studied by TaqMan Human MicroRNA Cards.
  • Five of these were validated by real-time RT-PCR. miR-139-3p, miR-541 and miR-765 were significantly differentially expressed between sporadic benign and von Hippel-Lindau-related pheochromocytomas.
  • Significantly higher expression of miR-885-5p and miR-1225-3p was found in multiple endocrine neoplasia type 2 and sporadic recurring pheochromocytomas, respectively.
  • Pathway analysis revealed the possible involvement of Notch- and G-protein-coupled receptor signaling in tumor recurrence.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Expression Profiling. MicroRNAs / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Cluster Analysis. Female. Gene Expression. Humans. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a / complications. Multiple Endocrine Neoplasia Type 2a / genetics. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818339.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


24. Ku YM, Shin SS, Lee CH, Semelka RC: Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. Top Magn Reson Imaging; 2009 Feb;20(1):11-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms.
  • This article describes the appearance of miscellaneous cystic and endocrine neoplasms using magnetic resonance imaging (MRI).
  • Magnetic resonance imaging is a useful diagnostic modality in the assessment of various pancreatic neoplasms.
  • Pancreatic endocrine tumors are moderately low in signal intensity on T1-weighted fat-suppressed images and moderately high in signal intensity on T2-weighted fat-suppressed images and demonstrate homogeneous, ring, or diffuse heterogeneous enhancement on immediate postgadolinium gradient echo images.
  • Cystic pancreatic neoplasms, including intraductal papillary mucinous neoplasm, are well demonstrated and subcategorized according to their characteristic cystic configurations on MRI and MR cholangiopancreatography images.
  • Mucinous cystic neoplasms usually appear as multilocular cystic masses, with benign forms of macrocystic tumors possessing uniform thickness septations and malignant forms exhibiting irregular septations and tumor nodules.
  • The presence of tumor stroma, invasion of adjacent tissue, or liver metastases can be assessed by MRI.
  • The connection between the pancreatic duct and the cystic tumor is usually well shown on MR cholangiopancreatography images.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Image Enhancement / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687721.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


25. Zhao Z, Wei Q, Zhao Y, Sun F, Jin X, Cui B, Ning G: Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules. Endocrine; 2009 Aug;36(1):155-60
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules.
  • Thyroid nodules were the extremely common endocrine tumors, in which papillary thyroid carcinomas (PTCs) were the most prevalent endocrine malignancy, representing 80-90% of all thyroid malignancies.
  • It was still a dilemma to discriminate PTCs and benign thyroid nodules.
  • With a new molecular genetics technology of Multiplex ligation-dependent probe amplification (MLPA), we investigated 13 PTC and 14 benign nodule tissue samples.
  • The results showed that PTCs had more genetic copy number alteration than benign nodules (P < 0.001).
  • Receiver operating characteristic (ROC) curve analysis suggested that genomic aberrations would provide a moderate accuracy method to discriminate PTCs and benign nodules.
  • The gain of interleukin 13 (IL-13) gene obviously identified the great difference between PTCs and benign nodules.
  • The current study showed that MLPA should be an effective method to diagnose PTCs and benign thyroid nodules, and also provided a clue to another relationship between IL-13 and PTCs.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Interleukin-13 / genetics. Neoplasms / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Gene Dosage. Genetic Testing / methods. Humans. Immunohistochemistry. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507063.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-13
  •  go-up   go-down


26. Fendrich V, Waldmann J, Feldmann G, Schlosser K, König A, Ramaswamy A, Bartsch DK, Karakas E: Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol; 2009 Apr;160(4):695-703
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia.
  • BACKGROUND: Epithelial and mesenchymal transitions (EMT) are essential for embryonic development and progression of non-invasive tumor cells into malignant, metastatic carcinomas.
  • During embryogenesis, the parathyroid glands develop from pharyngeal pouches and migrate to their final destinations, densely enclosed by mesenchymal neural crest cells.
  • In this study, we examined the expression of the EMT markers Snail, Twist and E-cadherin in normal parathyroid glands and benign and malignant parathyroid diseases.
  • METHODS: Using immunohistochemistry, we compared expression of E-cadherin, Snail and Twist in 25 patients with parathyroid adenoma, 25 patients with parathyroid hyperplasia, and nine patients with parathyroid cancer with normal parathyroid glands.
  • RESULTS: Normal parathyroid glands, parathyroid adenomas, and parathyroid hyperplasias showed a typical membranous E-cadherin staining pattern.
  • Snail and Twist positive cells were homogeneously distributed throughout the gland.
  • CONCLUSION: Expression of Snail and Twist at the invasive front and consecutive loss of E-cadherin in parathyroid carcinomas suggests a key role of EMT in the tumorigenesis of this cancer.
  • The unique expression pattern could help to distinguish between an adenoma and a non-metastatic carcinoma.
  • Loss of E-cadherin and change of the expression pattern of Snail and Twist together should result in an en bloc resection or a close follow-up.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176646.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Parathyroid Hormone; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / snail family transcription factors; SY7Q814VUP / Calcium
  •  go-up   go-down


27. Ozkaya M, Yuzbasioglu MF, Koruk I, Cakal E, Sahin M, Cakal B: Preoperative detection of insulinomas: two case reports. Cases J; 2008;1(1):362

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Insulinoma is the most common endocrine tumor of the pancreas.
  • We present two cases with benign pancreatic insulinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):987-92 [14500214.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):775-80 [12933480.001]
  • [Cites] Chir Ital. 2002 Sep-Oct;54(5):597-604 [12469455.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):552-5 [10805840.001]
  • [Cites] Surgery. 1998 Dec;124(6):1134-43; discussion 1143-4 [9854595.001]
  • [Cites] Br J Radiol. 1998 Jan;71(841):20-3 [9534694.001]
  • [Cites] J Am Coll Surg. 1999 Oct;189(4):368-73 [10509462.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2002 Aug;1(3):458-61 [14607727.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):152-5 [2169572.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):519-23 [1310159.001]
  • (PMID = 19040758.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633341
  •  go-up   go-down


28. Rubin MR, Bilezikian JP, Birken S, Silverberg SJ: Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol; 2008 Oct;159(4):469-74
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Preoperatively, it is difficult to differentiate between parathyroid cancer (PtCa) and severe primary hyperparathyroidism (PHPT) due to a benign tumor.
  • Human chorionic gonadotropin (hCG) is a tumor marker in trophoblastic and nontrophoblastic cancers and hyperglycosylated hCG is increased in hCG-secreting malignancies.
  • We investigated whether hCG can distinguish PtCa cancer from benign disease and add prognostic information.
  • RESULTS: Total urinary hCG was normal in the benign PHPT control subjects (range: 0-17 fmol/mg Cr; nl<50).
  • Serum malignant hyperglycosylated hCG values in all of the cancer patients exceeded the maximal serum malignant hCG level of the PHPT subjects with benign disease (3.77 pmol/l).
  • Further studies would help to elucidate the role of hCG as a potential tumor marker in this disease.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Exp Pathol. 1987 Dec;68(6):871-8 [2447930.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):145-50 [1646686.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):738-44 [1767540.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1829-42 [1372528.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4628-33 [1324787.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(6):461-6 [1282101.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1139-45 [7509735.001]
  • [Cites] Eur J Clin Invest. 1994 Feb;24(2):131-6 [7515807.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):757-62 [10091751.001]
  • [Cites] J Endocrinol. 1999 Apr;161(1):99-106 [10194533.001]
  • [Cites] Endocrine. 1999 Apr;10(2):137-44 [10451222.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):131-41 [15970647.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4803-7 [17214344.001]
  • [Cites] Cancer. 2007 May 1;109(9):1736-41 [17372919.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8 [17666472.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1553-6 [10789723.001]
  • [Cites] Clin Chem. 2003 May;49(5):808-10 [12709375.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):144-54 [12507971.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):497-506 [11874698.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):185-9 [11870503.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1254-9 [12748494.001]
  • [Cites] J Urol. 1987 Mar;137(3):502-4 [3820387.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Jan;54(1):57-63 [6274898.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):549-61 [15234236.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):39-45 [4734160.001]
  • (PMID = 18625691.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK074457-03; United States / NIDDK NIH HHS / DK / K24 DK074457; United States / NIDDK NIH HHS / DK / DK32333; United States / NCI NIH HHS / CA / R21 CA 98350; United States / NIDDK NIH HHS / DK / DK074457; United States / NIDDK NIH HHS / DK / K24 DK074457-03; United States / NCI NIH HHS / CA / R21 CA098350; United States / NIDDK NIH HHS / DK / R01 DK032333
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Naphthalenes; 0 / Parathyroid Hormone; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS247354; NLM/ PMC2970867
  •  go-up   go-down


29. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • Those that are mucinous, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), constitute the most important category, not only because they are the most common, but more importantly because they have well-established malignant potential, representing an adenomacarcinoma sequence.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • In contrast, the rare cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia such as the rare cystic ductal adenocarcinomas, cystic endocrine neoplasia, and most importantly, solid-pseudopapillary tumor (SPT) in which cystic change is so common that it used to be incorporated into its name ("solid-cystic," "papillary-cystic") are malignant neoplasia, albeit variable degrees of aggressiveness.
  • SPT holds a distinctive place among pancreatic neoplasia because of its highly peculiar characteristics, undetermined cell lineage, occurrence almost exclusively in young females, association with beta-catenin pathway, and also by being a very low-grade curable malignancy.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


30. Fareau GG, Vassilopoulou-Sellin R: Diagnostic challenges in adrenocortical carcinoma: recommendations for surveillance after surgical resection of selected adrenal nodules. Endocr Pract; 2007 Oct;13(6):636-41
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To discuss challenges in the diagnosis of adrenocortical carcinoma and to suggest surveillance measures after removal of selected adrenal nodules.
  • METHODS: We present the case of a 65-year-old man with worsening hypertension and new-onset hypokalemia attributed to primary hyperaldosteronism due to a 3-cm right adrenal nodule.
  • RESULTS: A laparoscopic right adrenalectomy was performed, and the histologic diagnosis was a benign adenoma.
  • CONCLUSION: Despite a comprehensive biochemical, radiologic, and histologic assessment, the diagnosis of adrenocortical carcinoma can be missed.
  • Particularly, we caution against undue reliance on the initial tumor size.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenal Glands / surgery. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adrenalectomy. Adrenocortical Adenoma / complications. Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / surgery. Aged. Humans. Hyperaldosteronism / complications. Hyperaldosteronism / pathology. Hypertension / etiology. Hypokalemia / etiology. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954420.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Imanaka M, Iida K, Takahashi K, Tsuji K, Nishizawa H, Fukuoka H, Takeno R, Takahashi Y, Okimura Y, Kaji H, Chihara K: The N131S mutation in the von Hippel-Lindau gene in a Japanese family with pheochromocytoma and hemangioblastomas. Endocr J; 2006 Dec;53(6):819-27
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • von Hippel-Lindau (VHL) disease (VHLD) is a hereditary autosomal dominant syndrome that causes various benign and malignant tumors.
  • VHLD is caused by mutations in the VHL tumor suppressor gene.
  • We also identified somatic loss of heterozygosity (LOH) at chromosome 3p25-26 in the adrenal tumor of the patient.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Cerebellar Neoplasms / genetics. Hemangioblastoma / genetics. Mutation. Pheochromocytoma / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001110.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


32. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • The use of these two markers sequentially in non-oncocytic lesions (testing HBME-1 as a second marker whenever galectin-3 proved negative) increased the sensitivity and specificity up to 97% and 95% respectively.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Luong TV, Salvagni S, Bordi C: Presacral carcinoid tumour. Review of the literature and report of a clinically malignant case. Dig Liver Dis; 2005 Apr;37(4):278-81
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presacral carcinoid tumour. Review of the literature and report of a clinically malignant case.
  • Carcinoid tumours arising in the presacral region are extremely rare and they are usually benign.
  • We report the case of a 37-year-old black man with a clinically malignant carcinoid tumour (well differentiated endocrine carcinoma) occurring in a sacrococcygeal teratoma and already metastasised to pelvic nodes, liver and bone at the time of the initial diagnosis.
  • [MeSH-major] Carcinoid Tumor / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Pelvic Floor / pathology. Pelvic Floor / radiography. Pelvic Neoplasms / secondary. Phosphopyruvate Hydratase / analysis. Sacrococcygeal Region. Synaptophysin / analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788213.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 15
  •  go-up   go-down


34. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P: Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer; 2008 Mar;15(1):337-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
  • Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall.
  • Nine patients with more than five type I gastric endocrine tumors each <1 cm in size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months.
  • This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Gastritis, Atrophic / drug therapy. Octreotide / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310299.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Chromogranin A; 0 / Gastrins; RWM8CCW8GP / Octreotide
  •  go-up   go-down


35. Conlon JM: Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regul Pept; 2010 Nov 30;165(1):5-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
  • Chromogranin A-like immunoreactivity (CgA-LI) has been, and remains, the most widely used diagnostic and prognostic marker for endocrine tumors.
  • However, circulating concentrations of CgA-LI are elevated in several non-neoplastic diseases and in patients receiving acid-suppression therapy which may lead to false positive diagnosis.
  • Additionally, certain endocrine tumors, such as rectal carcinoids, do not express the CgA gene so that there is a need for additional markers to complement CgA measurements.
  • Other CgA-derived peptides with potential as tumor markers are vasostatin-1, WE-14, catestatin, GE-25, and EL-35 but their value has yet to be fully assessed.
  • Circulating concentrations of chromogranin B-like immunoreactivity (CgB-LI) are not elevated in non-neoplastic diseases and measurements of CCB, the COOH-terminal fragment of CgB, may be useful as a biochemical marker for neuroendocrine differentiation in lung tumors.
  • Measurement of concentrations of a second secretogranin II-derived peptide, EM-66 in tumor tissue has been used to differentiate between benign and malignant pheochromocytoma.
  • These examples point to a limited although potentially valuable role for granin-derived peptides as tumor markers.
  • [MeSH-major] Chromogranins / metabolism. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19931574.001).
  • [ISSN] 1873-1686
  • [Journal-full-title] Regulatory peptides
  • [ISO-abbreviation] Regul. Pept.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranin B; 0 / Chromogranins; 0 / Secretogranin II
  •  go-up   go-down


36. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG: Familial pituitary tumor syndromes. Nat Rev Endocrinol; 2009 Aug;5(8):453-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial pituitary tumor syndromes.
  • The vast majority of pituitary tumors are benign and occur sporadically; however, they can still result in significant morbidity and even premature mortality through mass effects and hormone dysfunction.
  • Currently, four genes are known to be associated with familial pituitary tumor syndromes: MEN1, CDKN1B, PRKAR1A and AIP.
  • The first three genes are associated with a variety of extrapituitary pathologies, for example, primary hyperparathyroidism with multiple endocrine neoplasia type 1, which might aid identification of these syndromes.
  • Awareness and identification of familial pituitary tumor syndromes is important because of potential associated pathologies and important implications for family members.
  • Here, we review the current knowledge of familial pituitary tumor syndromes.
  • [MeSH-major] Genetic Predisposition to Disease. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology
  • [MeSH-minor] Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics. Cyclin-Dependent Kinase Inhibitor p27. Humans. Intracellular Signaling Peptides and Proteins / genetics. Multiple Endocrine Neoplasia / genetics. Multiple Endocrine Neoplasia / pathology. Proto-Oncogene Proteins / genetics. Syndrome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564887.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / MEN1 protein, human; 0 / PRKAR1A protein, human; 0 / Proto-Oncogene Proteins; 0 / aryl hydrocarbon receptor-interacting protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Number-of-references] 106
  •  go-up   go-down


37. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K, Lenders JW: Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer; 2008 Dec;15(4):1127-33
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
  • The treatment of choice for non-metastatic pheochromocytoma is surgical resection.
  • Its goals are to abolish catecholamine hypersecretion, normalize blood pressure, and prevent further tumor growth or progression to metastatic disease.
  • We here report a retrospective study on the long-term outcome after surgery for apparently benign pheochromocytoma at the Radboud University Nijmegen Medical Centre.
  • Survival was compared with survival of a matched reference population.
  • Two patients experienced a benign recurrence. Mean+/-s.d. follow-up was 10.2+/-7.5 (median 9, range 1-38) years.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Cardiovascular Diseases / mortality. Life Expectancy. Pheochromocytoma / secondary. Pheochromocytoma / surgery
  • [MeSH-minor] Adult. Aged. Blood Pressure. Catecholamines / blood. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824558.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


38. Nio K, Shimakami T, Yamashita T, Kagaya T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S, Kitagawa H, Kayahara M, Ohta T, Zen Y: [Two cases of a nonfunctioning pancreatic endocrine tumor found on a medical checkup]. Nihon Shokakibyo Gakkai Zasshi; 2009 Apr;106(4):560-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of a nonfunctioning pancreatic endocrine tumor found on a medical checkup].
  • Case 1) A 35-year-old man was admitted to our hospital for detailed examination of a 50-mm pancreas head tumor with surrounding lymph node swelling detected on medical checkup images.
  • Ultrasound-guided lymph node biopsy specimens gave a diagnosis of a nonfunctioning pancreatic neuroendocrine cancer, and adjuvant systemic chemotherapy was given after surgical resection of the tumor.
  • Case 2) A 52-year-old man was admitted to our hospital for detailed examination of an 18-mm pancreas head tumor detected by medical checkup FDG-PET images.
  • Imaging tests gave a diagnosis of a nonfunctioning pancreatic neuroendocrine tumor.
  • He underwent surgical resection, and the tumor was diagnosed as benign pathologically.
  • Both cases showed FDG-PET accumulation in the tumors irrespective of their malignant or benign nature.
  • Increased prevalence of FDG-PET checkup may increase the diagnosis of pancreatic neuroendocrine tumor in asymptomatic subjects.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346726.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


39. Chang MC, Xiao S, Nosé V: Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression. Hum Pathol; 2007 May;38(5):732-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression.
  • Pancreatic endocrine tumors (PETs), both functioning and nonfunctioning, are usually well differentiated and progress slowly.
  • A tumor associated with poorer prognostic features may be considered "uncertain" in behavior, but the malignant classifications are reserved for tumors showing clear signs of aggressive behavior.
  • Sporadic PETs resected or biopsied from 40 patients were identified and classified using WHO criteria (19 benign/uncertain, 21 malignant).
  • Utrophin localized to cell membranes (76% in malignant versus 21% in benign/uncertain PETs, P < .0006) and cyclin D1 staining showed nuclear positivity (67% in malignant versus 17% in benign/uncertain PETs, P < .003).
  • [MeSH-major] Cyclin D1 / physiology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Utrophin / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306326.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Utrophin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


40. Alasio TM, Vine A, Sanchez MA, Dardik H: Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature. Ann Diagn Pathol; 2005 Aug;9(4):234-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature.
  • Serous cystadenomas of the pancreas have been classified as benign exocrine tumors.
  • There have been rare cases of malignant behavior, and in exceptional cases, coexisting neoplasms have been reported.
  • We report a case of a coexistent neuroendocrine tumor identified within a serous cystadenoma in a 78-year-old woman, which was discovered incidentally after complete resection of the tumor.
  • Given the unpredictable metastatic potential of neuroendocrine tumors of the pancreas, we advocate complete resection of all pancreatic cystic tumors, combined with careful sampling of the pathological specimen to rule out a coexistent potentially malignant neoplasm.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084460.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Sassolas G, Hafdi-Nejjari Z, Schott AM, Bournaud C, Peix JL, Orgiazzi J, Dutrieux-Berger N, Borson-Chazot F, Group of Pathologists of the Rhône-Alpes Région: Geographical correlation between incidence of benign disease and that of cancer of the thyroid among the population of the Rhône-Alpes Région of France. Eur J Endocrinol; 2010 Jan;162(1):127-35
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographical correlation between incidence of benign disease and that of cancer of the thyroid among the population of the Rhône-Alpes Région of France.
  • OBJECTIVE: To analyze, at a population level, the relation between the incidences of benign thyroid diseases in patients submitted to surgery and that of thyroid cancers based on their respective geographical distributions.
  • METHODS: The study included 3169 cases (691 cancers and 2478 benign diseases) operated on in 2002 in the Rhône-Alpes région, which is subdivided into eight départements and 311 cantons.
  • In women, the incidence of microcancers was correlated to the thyroid intervention for benign pathologies rate.
  • In men, the incidence of supracentimetric cancers was related to the TIBR.
  • At the canton level, the relative risk of benign diseases was correlated to that of cancers.
  • CONCLUSION: In the Rhône-Alpes population with high rates of thyroid cancer incidence and of thyroid surgery, a number of correlations were found according to gender and tumor size.
  • However, the general incidence of cancer was not directly related to surgical activity.
  • Geographical variability may be related to the heterogeneous medical and pathological practices.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797258.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Moreover, 23 endocrine tumors with gastrointestinal origin were examined in order to test the applicability of this marker panel.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Instability. Microsatellite Repeats. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / genetics. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y: Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J; 2007 Feb;54(1):95-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of benign insulinoma using octreotide LAR: a case report.
  • In some patients with insulinoma, surgery is not possible due to either difficulties in detecting the tumor or advanced age.
  • We report a case of benign insulinoma using the long-acting octreotide formulation, octreotide long-acting repeatable (octreotide LAR), as a medical therapy.
  • An abdominal CT scan demonstrated a hypervascular tumor in the body of pancreas.
  • As the patient refused surgical resection of the pancreas tumor, we started to use the somatostatin analogue, octreotide, for treatment of hypoglycemia.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Insulinoma / drug therapy. Octreotide / therapeutic use. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124362.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Delayed-Action Preparations; 0 / Hemoglobin A, Glycosylated; 0 / Hemoglobins; 0 / Insulin; 0 / hemoglobin A1c protein, human; RWM8CCW8GP / Octreotide
  •  go-up   go-down


44. Zembowicz A, Garcia CF, Tannous ZS, Mihm MC, Koerner F, Pilch BZ: Endocrine mucin-producing sweat gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas. Am J Surg Pathol; 2005 Oct;29(10):1330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine mucin-producing sweat gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas.
  • Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is an underrecognized low-grade carcinoma with predilection to the eyelid.
  • The most common site of occurrence was the lower eyelid (8 cases).
  • Calponin, smooth muscle actin, and p63 immunohistochemical stains did not disclose myoepithelial cells around larger tumor nests in most cases, supporting the notion that EMPSGC is an invasive carcinoma.
  • In 10 cases, cystic areas lined by benign epithelium indistinguishable from eccrine ducts were present.
  • In some foci, the benign ductal epithelium was undermined or replaced by carcinoma in situ with similar cytologic features to the solid or papillary areas of EMPSGC.
  • The series provides histologic evidence for a multistage progression of noninvasive sweat gland neuroendocrine carcinoma to EMPSGC and then to mucinous carcinoma of the eyelid.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cheek / pathology. Eyelid Neoplasms / metabolism. Eyelid Neoplasms / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Korpershoek E, Stobbe CK, van Nederveen FH, de Krijger RR, Dinjens WN: Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas. Endocr Relat Cancer; 2010 Sep;17(3):653-62
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
  • Pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas (sPGLs) are catecholamine-producing tumors occurring in the context of hereditary tumor syndromes, with known germline mutations, and as sporadic tumors.
  • Since knowledge on intra-tumoral heterogeneity is important for understanding the pathogenesis of these tumors, we investigated 12 benign and 8 malignant PCCs and sPGLs for loss of heterozygosity (LOH) on DNA extracted from different regions of each tumor and from metastases.
  • Benign tumors were found to have less intra-tumoral heterogeneity (overall 8%) than malignant tumors (overall 23%), with the highest frequencies for chromosome 1p36 in the benign tumors (17%) and 1p13 and 3q24 in malignant tumors (both 38%).
  • In addition, differences in LOH patterns were detected between paired primary malignant tumors, and their metastases and different LOH patterns were observed in bilateral PCC of a multiple endocrine neoplasia type 2 patient.
  • We demonstrate that malignant PCC and sPGL have more intra-tumoral molecular heterogeneity than benign tumors, which suggests that benign and malignant PCC and sPGL have a different pathogenesis.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosomes, Human. Loss of Heterozygosity. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA, Neoplasm / genetics. Female. Genetic Variation. Histocytochemistry. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20488782.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


46. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P: Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol; 2010 Jun;17(6):1621-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.
  • BACKGROUND: Parenchyma-preserving resections (PPRs), including enucleation and middle pancreatectomy (MP), are accepted procedures for insulinomas, but their role in the treatment of nonfunctioning pancreatic endocrine tumors (NF-PETs) is debated.
  • Patients with multiple endocrine neoplasia type 1 were excluded.
  • At pathology, there were 34 (68%) benign lesions, 13 (26%) neoplasms of uncertain behavior, and 3 (6%) well-differentiated carcinomas.
  • Overall, four patients (8%) experienced tumor recurrence after a mean of 68 months.
  • The incidence of exocrine/endocrine insufficiency was 8%.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162460.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. d'Assignies G, Couvelard A, Bahrami S, Vullierme MP, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P, Vilgrain V: Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology; 2009 Feb;250(2):407-16
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.
  • PURPOSE: To prospectively correlate multidetector computed tomographic (CT) perfusion measurement of pancreatic endocrine tumors with tumor microvascular density (MVD) assessed by using histologic techniques and to determine whether perfusion CT parameters differ between tumor grades.
  • Thirty-six patients (15 men, 21 women; mean age, 53 years; range, 18-78 years) with resectable pancreatic endocrine tumors underwent presurgical dynamic perfusion CT.
  • Multidetector CT perfusion data were analyzed to calculate tumor and normal pancreatic blood flow, blood volume, mean transit time, and permeability-surface area product.
  • Multidetector CT perfusion parameters were compared with intratumoral MVD by using the Spearman correlation coefficient and with World Health Organization (WHO) classification, tumor size, tumor proliferation index, hormonal profile, and presence of metastases by using Mann-Whitney tests.
  • RESULTS: High correlation (r = 0.620, P < .001) was observed between tumor blood flow and intratumoral MVD.
  • Blood flow was significantly higher (P = .02) in the group of benign tumors (WHO 1) than in the groups of tumors of indeterminate prognosis (WHO 2) or well-differentiated carcinomas (WHO 3).
  • CONCLUSION: Perfusion CT is feasible in patients with pancreatic endocrine tumors and reflects MVD.
  • [MeSH-major] Neovascularization, Pathologic / radiography. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiographic Image Interpretation, Computer-Assisted. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095784.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Tajima S, Maeda I, Kanemaki Y, Nakajima Y, Tatsunami S, Fukuda M, Takagi M: Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma. Pathol Int; 2010 Jun;60(6):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma.
  • Endocrine ductal carcinoma in situ (E-DCIS) is an intraductal carcinoma characterized by endocrine features and expression of neuroendocrine markers.
  • However, the former is an intraductal carcinoma, and the latter is an intraductal benign lesion.
  • However, it is considered that E-DCIS diagnosis is possible by diffuse immunopositivity of CD56 after having been based on histopathology.
  • [MeSH-major] Antigens, CD56 / metabolism. Antigens, CD57 / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged. Reproducibility of Results. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pathol Int. 2011 Jan;61(1):49-51 [21166944.001]
  • (PMID = 20518901.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD57; 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Lasalandra C, Coviello M, Falco G, Divella R, Trojano G, Laterza AM, Quero C, Pepe V, Zito FA, Quaranta M: Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases. Int J Gynecol Cancer; 2010 May;20(4):507-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases.
  • Adipose tissue is a major endocrine and it secretes hormones termed adipokines.
  • This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin.
  • Diagnosis of benign and malignant gynaecological diseases was established by biopsy.
  • RESULTS: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient.
  • Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases.
  • A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found.
  • CONCLUSIONS: This is one of the first report on adiponectin in benign and malignant gynecological diseases.
  • [MeSH-major] Adiponectin / blood. Biomarkers, Tumor / blood. Genital Diseases, Female / blood. Neoplasms / blood. Vascular Endothelial Growth Factor A / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442584.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


50. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol; 2010 Jun;23(6):824-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
  • Pancreatic endocrine tumors are rare diseases and devising a clinically effective prognostic stratification of patients is a major clinical challenge.
  • This study aimed at assessing whether the tumor-node-metastasis (TNM)-based staging and proliferative activity-based grading recently proposed by the European NeuroEndocrine Tumors Society (ENETS) have clinical value.
  • TNM was applied to 274 patients with histologically diagnosed pancreatic endocrine tumors operated from 1991 to 2005, with last follow-up at December 2007.
  • According to World Health Organization (WHO) classification, 246 were well-differentiated neoplasms (51 benign, 56 uncertain behavior, 139 carcinomas) and 28 poorly differentiated carcinomas.
  • Survival analysis not only ascertained the prognostic value of the TNM system but also highlighted that in the absence of nodal and distant metastasis, infiltration and tumor dimensions over 4 cm had prognostic significance.
  • In conclusion, WHO classification assigns clinically significant diagnostic categories to pancreatic endocrine tumors that need prognostic stratification by applying a staging system.
  • The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS-TNM; it (i) assigns a risk of death proportional to the stage at the time of diagnosis, and (ii) allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition.
  • [MeSH-major] Carcinoma / diagnosis. Cell Proliferation. Ki-67 Antigen / analysis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Italy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Time Factors. World Health Organization


51. Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A, Ruszniewski P: Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas; 2005 Jul;31(1):79-83
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?
  • OBJECTIVES: Pancreatic endocrine tumors (PETs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are rare diseases of the pancreas.
  • Cases of association of endocrine and exocrine neoplasms of the pancreas have been reported, corresponding to mixed or amphicrine tumors.
  • RESULTS: Preoperative diagnosis was unspecified pancreatic tumor (n = 1), IPMN (n = 2), and association of PET and IPMN (n = 3).
  • IPMN involved the main pancreatic duct in 4 patients and was classified as benign (n = 4), borderline (n = 1), or malignant noninvasive (n = 1).
  • CONCLUSION: This study describes a new aspect of endocrine-exocrine pancreatic neoplasm association.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968252.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 9007-92-5 / Glucagon
  •  go-up   go-down


52. He X, Wei Q, Zhang X, Xiao J, Jin X, Zhu Y, Cui B, Ning G: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract; 2010 Oct 15;206(10):712-5
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In different tumor entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumor dissemination and poor prognosis.
  • The aim of this study was to examine the immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In our study, the CXCR4 expression of the thyroid carcinoma group (including 16 papillary thyroid carcinomas, 18 follicular thyroid carcinomas, 9 poorly differentiated thyroid carcinomas, and 7 medullary thyroid carcinomas) was found to be higher than in the benign lesion group (including 19 cases of Hashimoto's thyroiditis, 15 nodular goiters, and 50 follicular adenomas) (p<0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Receptors, CXCR4 / analysis. Thyroid Diseases / immunology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Carcinoma. Carcinoma, Neuroendocrine. Cell Differentiation. Child. Female. Goiter, Nodular / immunology. Hashimoto Disease / immunology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Thyroid Neoplasms / immunology. Thyroid Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20646838.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; Thyroid cancer, medullary; Thyroid cancer, papillary
  •  go-up   go-down


53. Deschamps L, Handra-Luca A, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J, Bedossa P, Couvelard A: CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol; 2006 Jul;37(7):802-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival.
  • Immunohistochemical expression of CD10 was examined in 91 pancreatic endocrine tumors (PETs) included in tissue microarrays and representing various stages of tumorigenesis as well as in 10 normal pancreas tissues.
  • Epithelial cytoplasmic expression of CD10 increased with World Health Organization classification: CD10 was detected in 12% of benign tumors, 29% of tumors of uncertain prognosis, 38% of well-differentiated carcinomas, and 86% of poorly differentiated carcinomas.
  • Expression of CD10 also correlated significantly with a high proliferative index (P = .020), low microvascular density (P = .043), large tumor size (P = .023), and presence of metastasis (P = .013).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neprilysin / biosynthesis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784978.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


54. Waldmann J, Fendrich V, Holler J, Buchholz M, Heinmöller E, Langer P, Ramaswamy A, Samans B, Walz MK, Rothmund M, Bartsch DK, Slater EP: Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer; 2010 Sep;17(3):743-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
  • The diagnosis of a malignant pheochromocytoma (PC) can only be established by the presence of distant metastases, but a subset of apparently benign PCs develop metastases.
  • We have employed a microarray analysis to identify a typical gene expression profile which distinguishes malignant from benign PC.
  • Total RNA was isolated from fresh-frozen tissue of five benign and five malignant PCs.
  • The analysis revealed a more than twofold difference in expression between benign and malignant PCs in 132 genes: 19 were up-regulated and 113 were down-regulated.
  • Comparative analysis by microarray of all ten PCs (benign/malignant) versus normal adrenal medulla revealed a more than twofold expression difference in 455/539 and 491/671 genes respectively.
  • Several of these genes are known to participate on adrenal tumorigenesis, potential tumor suppressor genes, and oncogenes.
  • Comprehensive gene expression analysis of malignant and benign PCs revealed different gene profiles, which could be used to discriminate between malignant and benign PCs.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Medulla / metabolism. Biomarkers, Tumor / metabolism. Gene Expression Profiling. Pheochromocytoma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


55. Srinivasan VD, Wayne JD, Rao MS, Zynger DL: Solitary fibrous tumor of the pancreas: case report with cytologic and surgical pathology correlation and review of the literature. JOP; 2008;9(4):526-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pancreas: case report with cytologic and surgical pathology correlation and review of the literature.
  • CONTEXT: Solitary fibrous tumor is an uncommon spindle cell tumor which can occur in a variety of locations.
  • Four cases of pancreatic solitary fibrous tumor have been reported in the literature.
  • CASE REPORT: We report the fifth case of pancreatic solitary fibrous tumor in a 78-year-old woman who presented with back pain and weight loss.
  • Imaging studies were suggestive of an endocrine tumor.
  • Endoscopic ultrasound with fine needle aspiration was performed and revealed a benign mesenchymal tumor, which is the first successful report of cytology on a pancreatic solitary fibrous tumor.
  • The patient underwent a distal pancreatectomy with resection of the mass which was diagnosed as solitary fibrous tumor, supported by immunohistochemical studies showing positivity for CD99, vimentin, bcl-2, and CD34.
  • CONCLUSION: Diagnosing pancreatic solitary fibrous tumor is challenging due to its rarity, nonspecific clinical presentation, and difficulty to be radiologically distinguished from other pancreatic lesions.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Solitary Fibrous Tumors / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Rare Diseases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648147.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 7
  •  go-up   go-down


56. Jia H, Jiang X, Zhao Z, Ge Y, Lu J, Zhao Y, Cui B, Ning G: High frequency of down-regulation of E-cadherin detected in benign sporadic insulinomas by multiplex ligation-dependent probe amplification. Hum Pathol; 2009 Sep;40(9):1336-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of down-regulation of E-cadherin detected in benign sporadic insulinomas by multiplex ligation-dependent probe amplification.
  • Insulinomas are the most common functioning pancreatic endocrine tumors, and the previous studies showed that the chromosomal aberrations of Chr.9q, 11q, and 22q were associated with the development and progression of insulinoma.
  • To analyze the genetic alterations in sporadic insulinoma, we tested 23 tumor samples using multiplex ligation-dependent probe amplification.
  • The results showed that 20 (87%) of the 23 patients had lost CDH1, a tumor suppressor gene.
  • Immunofluorescence analysis of the E-cadherin and beta-catenin proteins further confirmed the impaired expression of E-cadherin and the translocation of beta-catenin in sporadic insulinomas.
  • It was found that the cytoplasmic accumulation of beta-catenin coincided with the decrease or loss of E-cadherin synthesis during the tumorigenesis of sporadic insulinomas.
  • Our study suggests that the inactivation of CDH1 is an important and early event in the development of these tumor types.
  • [MeSH-major] Cadherins / genetics. Insulinoma / genetics. Nucleic Acid Amplification Techniques / methods. Pancreatic Neoplasms / genetics. beta Catenin / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427668.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


57. Uchida K, Toriumi Y, Kawase K, Tabei I, Yamashita A, Nogi H: Percutaneous endoscopy-guided biopsy of an intracystic tumor with a mammary ductoscopy. Breast Cancer; 2007;14(2):215-8
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous endoscopy-guided biopsy of an intracystic tumor with a mammary ductoscopy.
  • METHODS: An endoscope was inserted into the cyst percutaneously, and the intracystic tumor was biopsied using forceps.
  • Four of six cases were cancer, and two were benign papillomas.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast Cyst / pathology. Endoscopy / methods. Mammary Glands, Human / pathology
  • [MeSH-minor] Aged. Breast / pathology. Breast Neoplasms / pathology. Endoscopes. Female. Humans. Middle Aged. Nipples / secretion. Papilloma / pathology

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485908.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Müller MW, Assfalg V, Michalski CW, Büchler P, Kleeff J, Friess H: [Middle segmental pancreatic resection: an organ-preserving option for benign lesions]. Chirurg; 2009 Jan;80(1):14-21
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Middle segmental pancreatic resection: an organ-preserving option for benign lesions].
  • Benign and low malignant tumors of the middle pancreatic segment can be resected by extended pancreaticoduodenectomy or distal pancreatic resection.
  • Both procedures involve unavoidably extensive loss of normal pancreatic parenchyma, leading to deteriorated endocrine and exocrine pancreatic function.
  • Normal pancreatic tissue can be preserved as only the tumor with a pancreatic segment is resected.
  • Several reports confirm lower mortality and minimal risk of postoperative endocrine or exocrine insufficiency than with standard pancreatic resections.
  • The indication should be limited exclusively to benign or low malignant pancreatic tumors, metastases from other tumors, and focal chronic pancreatitis, as this type of resection cannot be deemed oncologic.
  • [MeSH-major] Minimally Invasive Surgical Procedures / methods. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Pancreatitis / surgery. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):730-3 [8751242.001]
  • [Cites] World J Surg. 2003 May;27(5):595-8 [12715230.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):909-18; discussion 918-20 [17122616.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):967-71 [11490850.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1441-7 [11374680.001]
  • [Cites] HPB (Oxford). 2006;8(2):142-7 [18333263.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):871-6 [15194067.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Surg Gynecol Obstet. 1959 Oct;109:473-8 [14416087.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):263-7 [11941971.001]
  • [Cites] Am J Surg. 1997 Apr;173(4):257-63 [9136776.001]
  • [Cites] Arch Surg. 1987 Apr;122(4):416-20 [3566523.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):403-13 [1015887.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):512-9; discussion 519-23 [10522721.001]
  • [Cites] Int Surg. 2000 Oct-Dec;85(4):297-302 [11589595.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):631-5; discussion 635-6 [12488196.001]
  • [Cites] Surg Today. 1993;23(8):733-6 [8400678.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):132-9 [1546898.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):453-5 [11180870.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1713-5 [12397773.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):125-30; discussion 130-1 [1733360.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1270-3 [7552016.001]
  • [Cites] Chirurgie. 1998 Sep;123(4):363-7 [9828510.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2002 Dec;65(12):608-13 [12636207.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(6):733-7 [12658408.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Surgery. 1985 Apr;97(4):467-73 [3983823.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • (PMID = 19011818.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 42
  •  go-up   go-down


59. Paramo JC, Mesko T: Age, tumor size, and in-office ultrasonography are predictive parameters of malignancy in follicular neoplasms of the thyroid. Endocr Pract; 2008 May-Jun;14(4):447-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, tumor size, and in-office ultrasonography are predictive parameters of malignancy in follicular neoplasms of the thyroid.
  • OBJECTIVE: To identify clinical predictors of malignancy in patients with intraoperative frozen-section diagnosis of follicular neoplasm of the thyroid.
  • METHODS: We performed a retrospective cross-sectional study of 71 patients with intraoperative frozen-section diagnosis of follicular neoplasm who underwent thyroidectomy between January 1992 and December 2000.
  • Age, sex, tumor size, and in-office ultrasonography characteristics of the lesions were assessed.
  • These clinical factors were compared between cases that had benign definitive pathologic findings and those that were found to be carcinomas on permanent sections.
  • RESULTS: Nine (13%) of the 71 follicular neoplasms were found to be carcinomas after definitive pathologic evaluation.
  • When the in-office ultrasonography findings were interpreted as benign, only 7% (3/46) of cases were malignant compared with 40% (4/10) when the ultrasonography findings were suspicious (P = .02).
  • CONCLUSIONS: Age and tumor size are predictive parameters of malignancy in follicular neoplasm of the thyroid.
  • Total thyroidectomy is reasonable in patients with follicular neoplasm on frozen section if they are young (<45 years old), with large (>4 cm) tumors or if there are suspicious findings on in-office ultrasonography.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / pathology. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Age Factors. Cross-Sectional Studies. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558598.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ: Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol; 2006 Sep;30(9):1140-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
  • Commonly there is a long lag time between diagnosis and clinical evidence of malignant behavior even in histopathologically straightforward lesions.
  • There is therefore a need for a novel adjunctive marker to assist in the diagnosis of carcinoma.
  • Parafibromin is the protein encoded by the putative tumor suppressor gene HRPT2.
  • Mutations predicted to inactivate parafibromin were first detected in the germline of patients with hyperparathyroidism-jaw tumor (HPT-JT) syndrome.
  • We performed immunohistochemistry for parafibromin on 115 parathyroid tissues comprising 4 HPT-JT-related tumors (3 adenomas and 1 carcinoma), 11 sporadic parathyroid carcinomas, 79 sporadic adenomas, 3 multiple endocrine neoplasia 2A-related adenomas, 2 sporadic primary hyperplasias, 2 multiple endocrine neoplasia (MEN)-1-related hyperplasias, 6 secondary hyperplasias, 4 tertiary hyperplasias, and 4 normal parathyroid glands.
  • There was complete absence of nuclear staining in 3 of 4 (75%) HPT-JT-related tumors and 8 of 11 (73%) sporadic parathyroid carcinomas and focal weak staining in 1 of 4 HPT-JT tumors and 2 of 11 sporadic parathyroid carcinomas.
  • In contrast, 98 of 100 non-HPT-JT-related benign parathyroids showed diffuse strong nuclear positivity and 2 of 100 showed weak positive staining.
  • We conclude that, in the correct clinical and pathologic context, complete absence of nuclear staining for parafibromin is diagnostic of parathyroid carcinoma or an HPT-JT-related tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Hyperparathyroidism / complications. Jaw Neoplasms / complications. Parathyroid Glands / pathology. Parathyroid Neoplasms / diagnosis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Cell Nucleus / chemistry. Humans. Hyperplasia. Immunohistochemistry. Multiple Endocrine Neoplasia / chemistry. Syndrome

  • Genetic Alliance. consumer health - Hyperparathyroidism-jaw tumor syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931959.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


61. Garcia EA, Simões K, Wakamatsu A, Ressio RA, Alves VA, Longatto-Filho A, Camargo RS: Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol; 2010 Jun;21(2):101-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions.
  • Thyroid cancer is the most frequent endocrine neoplasia worldwide.
  • In order to evaluate the value of LVD in benign and malignant thyroid lesions, we analyzed 110 thyroidectomy specimens using D2-40, a specific marker for lymphatic vessels and vascular endothelial growth factor C (VEGF-C), the most potent molecule of lymphatic proliferation.
  • VEGF-C was more markedly expressed in malignancies than in benign lesions (p = 0.0001).
  • Almost all cancers with high positive VEGF-C expression also exhibited increased peritumoral LVD (p = 0.049) when compared with the benign lesions.
  • Indeed, the high peritumoral LVD of malignant thyroid lesions is an important finding for surgery planning and supports the practice of total thyroidectomy in malignant thyroid neoplasm's since the lymphatic peritumoral vessels definitely are an escape path for tumor cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphatic Vessels / pathology. Thyroid Neoplasms / pathology. Vascular Endothelial Growth Factor C / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336393.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C; 0 / monoclonal antibody D2-40
  •  go-up   go-down


62. Menéndez-Skertchly AL, Ortiz-Hidalgo C, Quijano-Orvańanos F, Cervantes-Monteil F, Chousleb-Kalach A, Padilla-Longoria R, Godoy-Valdés S, Vidal-González P, Herrera MF: [Endocrine tumors of the pancreas: experience in the ABC Medical Center]. Rev Gastroenterol Mex; 2006 Jul-Sep;71(3):296-301
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumors of the pancreas: experience in the ABC Medical Center].
  • [Transliterated title] Tumores endocrinos del páncreas: experiencia en el Centro Médico ABC.
  • OBJECTIVES: To analyze presentation, diagnosis and treatment of islet cell tumors at the ABC Medical Center.
  • MATERIALS AND METHODS: Medical records of the 7 patients with endocrine tumors diagnosed between 1995 and 2005 were reviewed and analyzed, with emphasis to clinical, biochemical and radiological characteristics, surgical treatment and outcome.
  • RESULTS: There were 3 insulinomas, 1 gastrinoma, 1 VIPoma, and 2 non-functioning tumors.
  • The tumor was localized before surgery in 2 cases.
  • In all patients intraoperative ultrasound confirmed the tumor and enucleation was performed in all three.
  • A tumor in the pancreatic head was found and it was resected by pancreaticoduodenectomy.
  • Both non functioning tumors were found by imaging studies, one benign tumor was treated by central pancreatectomy and the other was malignant and underwent distal en-block pancreatectomy.
  • Immunohistochemistry was positive for VIP in the benign lesion.
  • Imaging studies localized the tumor in 7 of the 8 patients.
  • Surgical resection cured all benign tumors.
  • [MeSH-major] Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140051.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


63. Long KB, Srivastava A, Hirsch MS, Hornick JL: PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol; 2010 May;34(5):723-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
  • However, PAX8 expression has not previously been examined in pancreatic endocrine tumors (PETs).
  • Expression of PAX8 was significantly associated with WHO category 1.1 ("benign" behavior) compared with category 1.2 (uncertain behavior) or 2 (well-differentiated endocrine carcinoma) (positive in 100%, 64%, and 52% of tumors, respectively; P<0.05).
  • PAX8 immunostaining may be helpful in determining the primary site for a WDNET metastatic to the liver, as ileal (PAX8 negative) and pancreatic (PAX8 positive) tumors most often present as a metastasis from an occult primary.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoid Tumor / pathology. Carcinoma, Islet Cell / secondary. Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Paired Box Transcription Factors / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Dec;35(12):1906-8 [22067332.001]
  • (PMID = 20414099.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


64. Tanaka K, Komoike Y, Egawa C, Motomura K, Koyama H, Nagumo S, Kataoka TR, Inaji H: Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases. Breast Cancer; 2009;16(1):77-82
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases.
  • Mucocele-like tumor (MLT) of the breast is a mucinous disorder that is generally difficult to distinguish from mucinous carcinoma.
  • Moreover, MLT is often accompanied by atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS), and preoperative diagnosis is very confusing.
  • Ultimately, excisional biopsies were performed to obtain a correct diagnosis in all cases.
  • Immunohistochemical staining of MLTs accompanied by ADH or DCIS (malignant MLTs) revealed the presence of MUC6, while MLTs without ADH or DCIS (benign MLTs) were MUC6-negative.
  • Immunohistochemical staining for MUC6 may be useful in differentiating between benign MLTs and malignant MLTs, although further investigation is needed.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Biopsy, Fine-Needle. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478314.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol; 2009 Jan;104(1):171-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
  • OBJECTIVES: Pancreatic endocrine tumors represent morphologically and biologically heterogeneous neoplasms.
  • Well-differentiated endocrine tumors (benign or of uncertain behavior) can be distinguished from well-differentiated and poorly differentiated endocrine carcinomas.
  • Although many well-differentiated endocrine carcinomas show rather low rates of tumor growth, more than two-thirds of pancreatic endocrine carcinomas display distant metastases at the time of diagnosis.
  • As the currently applied therapies beyond surgery only achieve partial or complete response rates of approximately 15%, additional chemotherapeutic targets are needed, especially in the therapy of inoperable and progressive pancreatic endocrine carcinomas.
  • METHODS: The expression of epidermal growth factor receptor (EGFR) and cyclooxygenase (COX)-2 were investigated in 110 clinically and pathomorphologically well-characterized pancreatic endocrine tumors, using immunohistochemistry and immunoblot analyses.
  • RESULTS: The expression of EGFR correlated significantly with the grade of malignancy, increasing from low rates of expression in benign tumors and tumors of uncertain behavior to high rates of expression in well- and poorly differentiated endocrine carcinomas.
  • CONCLUSIONS: Our results suggest that EGFR and COX-2 may represent useful additional chemotherapeutic targets in pancreatic endocrine tumors.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Pancreatic Neoplasms / metabolism. Pyrazoles / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Sulfonamides / therapeutic use. Tyrphostins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Apoptosis / drug effects. Blotting, Western. Carcinoid Tumor / metabolism. Celecoxib. Cell Line, Tumor. Cell Survival / drug effects. Cyclooxygenase 2 Inhibitors / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Insulinoma / metabolism. Male. Mice. Mice, Transgenic. Middle Aged. Quinazolines. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098866.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; 0 / Tyrphostins; 170449-18-0 / tyrphostin AG 1478; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


66. Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B, Adams KT, Ohta S, Wesley RA, Eisenhofer G, Pacak K: Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine; 2008 Aug-Dec;34(1-3):96-100
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma.
  • Signs and symptoms associated with pheochromocytomas are predominantly caused by catecholamine excess, but tend to be highly variable and non-specific.
  • In this study, we evaluated 23 male and 35 female pheochromocytoma patients for symptoms and signs of pheochromocytoma with special regard to gender-related differences in presentation.
  • Subgroup analyses and multiple regression analysis revealed gender differences to be irrespective of benign or malignant disease, use of adrenoceptor-blockade, age and biochemical phenotype.
  • We conclude female patients have significantly more self-reported pheochromocytoma signs and symptoms than male patients irrespective of biochemical phenotype and tumor presentation which may be related to distinct catecholamine receptor sensitivity.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis. Sex Characteristics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982461.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


67. Delle Fave G, Capurso G, Milione M, Panzuto F: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):659-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumours of the stomach.
  • Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells.
  • Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology.
  • In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases.
  • [MeSH-major] Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Neoplasm Invasiveness / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrectomy / methods. Gastric Mucosa / pathology. Gastroscopy / methods. Humans. Immunohistochemistry. Incidence. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology. Zollinger-Ellison Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253892.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 63
  •  go-up   go-down


68. Sibio S, Borrini F, Sammartino P, Accarpio F, Biacchi D, Caprio G, Iafrate F, Baccheschi AM, Cornali T, Di Giorgio A: Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features. Endocr Pathol; 2010 Sep;21(3):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features.
  • Brenner tumor and struma ovarii, two uncommon ovarian tumors arising alone or together with dermoid cysts or adenomas, are both rare entities.
  • Few published reports describe coexisting Brenner tumor and malignant struma ovarii.
  • Patients in whom these malignancies coexist only occasionally have peritoneal spreading, strumosis, or a history of thyrotoxicosis.
  • The mass consisted predominantly of a Brenner tumor associated with struma ovarii containing a single small island of thyroid tissue that had undergone malignant transformation into a well-differentiated papillary carcinoma and also normal thyroid tissue that had spread to the peritoneum.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Papillary / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Struma Ovarii / secondary
  • [MeSH-minor] Aged. Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Female. Humans. Neoplasms, Second Primary / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532676.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Carney JA: Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab; 2009 Oct;94(10):3656-62
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for carney triad .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors.
  • BACKGROUND: Two young women, each with paraganglioma and gastric stromal tumor, were encountered in the middle 1970s.
  • Five additional patients with gastric stromal tumor, paraganglioma, and pulmonary chondroma were found, and all were young women.
  • The gastric lesion was usually the presenting tumor (75%), followed by the lung lesion (15%) and the paraganglionic tumor (10%).
  • The pulmonary tumors were asymptomatic and benign.
  • FOLLOW-UP: At follow-up, 80% of the patients were alive, two thirds with pulmonary chondroma, 25% with metastatic or residual gastric stromal tumor, and 5% with primary or metastatic paraganglioma.
  • Twenty percent of the patients were dead, usually from metastatic gastric stromal tumor, less frequently from metastatic paraganglioma.
  • CONCLUSION: The Carney triad is a chronic, persistent, indolent but sometimes fatal disorder of unknown etiology.
  • [MeSH-major] Adenoma. Adrenal Cortex Neoplasms. Chondroma. Esophageal Neoplasms. Leiomyoma. Lung Neoplasms. Multiple Endocrine Neoplasia. Neoplastic Syndromes, Hereditary / pathology. Paraganglioma
  • [MeSH-minor] Adolescent. Carotid Body Tumor / pathology. Chronic Disease. Female. Follow-Up Studies. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Pheochromocytoma / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723753.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


70. Tena-Suck ML, Ortiz-Plata A, Galán F, Sánchez A: Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol; 2009 Apr;13(2):82-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor.
  • Craniopharyngiomas are benign tumors of the sellar region generally associated with endocrine disorders and often locally aggressive.
  • The reliable criteria for predicting the tumor behavior are still lacking.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • The aim of this study was to evaluate the activity and correlation of epithelial cell adhesion molecule (Ep-CAM) and pituitary tumor transforming gene (PTTG-1) immunoexpression that is possibly related to relapse in 40 patients with adamantinomatous craniopharyngioma.
  • The Ep-CAM and PTTG-1 expression in craniopharyngioma could be used as prediction markers of relapsing tumor.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Craniopharyngioma / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Recurrence, Local / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Male. Securin

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Diagn Pathol. 2009 Dec;13(6):428-9 [19917481.001]
  • (PMID = 19302955.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  •  go-up   go-down


71. Teh SH, Deveney C, Sheppard BC: Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg; 2007 May;193(5):610-3; discussion 613
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
  • BACKGROUND: Benign and malignant pancreatic neuroendocrine tumors (PNETs) are rare, and long-term outcome is generally poor without surgical intervention.
  • Five patients had multiple endocrine neoplasms syndrome, and 1 patient had von Hippel-Lindau syndrome.
  • There were 20 benign (9 functional) and 13 malignant (6 functional) neoplasms.
  • Mean tumor size was 4.2 cm, and multiple tumors were noted in 10 patients.
  • The 1-, 3-, and 5-year overall survival rates for patients with benign versus malignant neoplasms were 100% vs. 92%, 89% vs. 64%, and 89% vs 36% (P = .01), respectively.
  • The 1-, 3-, and 5-year disease progression rates for patients with malignant neoplasms were 13%, 63%, and 100%, respectively (P < .0001).
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery


72. Tomita T: Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy. Islets; 2010 Mar-Apr;2(2):82-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy.
  • This study is aimed to immunocytochemically identify cleaved caspase-3 (CC-3) positive cells in pancreatic endocrine tumors (PETs) compared with control islets.
  • Since 21 of 24 (88%) of potentially malignant primary non-β-cell PETs were negative, whereas 5 of 12 (42%) benign insulinomas were positive for CC-3 immunostaining, CC-3 negative immunostaining may serve as a possible malignant marker for all PETs.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Caspase 3 / metabolism. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Diagnostic Techniques, Endocrine. Female. Humans. Immunohistochemistry / methods. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Male. Middle Aged. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / metabolism. Neuroendocrine Tumors / pathology. Protein Processing, Post-Translational / physiology. Rabbits. Staining and Labeling / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099299.001).
  • [ISSN] 1938-2022
  • [Journal-full-title] Islets
  • [ISO-abbreviation] Islets
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 3; Pancreatic islet cell tumors
  •  go-up   go-down


73. Yang YS, Wang XD, Ji DG, Zhang D, Xie YJ, Meng ZH, Zhang XW: [Middle segment pancreatectomy for the benign tumors of the neck and body of the pancreas (report of 15 cases)]. Zhonghua Wai Ke Za Zhi; 2010 Sep 15;48(18):1402-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Middle segment pancreatectomy for the benign tumors of the neck and body of the pancreas (report of 15 cases)].
  • OBJECTIVE: To study the clinical application value of middle segment pancreatectomy in the treatment of benign tumors of the amphi-neck of the pancreas.
  • They all received middle segment pancreatectomy for benign tumors of the amphi-neck of the pancreas.
  • Postoperative pathology showed that in the 15 patients, 1 got solid-pseudopapillary tumor of the pancreas, 3 got non-functional islet cell tumor, 11 got cystadenoma of pancreas.
  • CONCLUSIONS: There is an exact therapeutic effect of middle segment pancreatectomy for benign tumors of the amphi-neck of the pancreas.
  • The treatment has little function damage to patients' endocrine and external secretion.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092576.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Meiler R, Dietl KH, Novák K, Patzel C: [Intrapancreatic accessory spleen]. Rozhl Chir; 2009 Apr;88(4):165-9
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ektope Milz als tumor im Pankreas.
  • PATIENT: A 63-year-old man admitted for Cholezystitis was incidencially diagnosed with a tumor at the pancreatic tail.
  • Due to inhomogenous enhancement on the early vascular phase the diagnosis of a endocrine pancreatic tail Carcinoma was suspected.
  • An oncological left pancreatectomy was performed suspecting a malignant tumor.
  • CONCLUSION: Intrapancreatic accessory spleen is a rare cause of unnecessary laparotomy but the absence of reliable diagnostics for this entity make histological ascertainment of a benign tumor indispensable.
  • Therefore we still need an oncological tumor resection.
  • [MeSH-major] Choristoma / diagnosis. Pancreatic Diseases / diagnosis. Spleen

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645140.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


75. Fasanella KE, McGrath KM, Sanders M, Brody D, Domsic R, Khalid A: Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality. Gastrointest Endosc; 2009 May;69(6):1074-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality.
  • BACKGROUND: The clinical course of pancreatic endocrine tumors (PET) depends on tumor size, the presence of invasion or metastasis, the Ki-67 index, mitoses per high power field, and mutational damage.
  • OBJECTIVE: To evaluate PET EUS-guided FNA (EUS-FNA) microsatellite loss analysis in the context of PET-related mortality.
  • Malignant PET contained multiple microsatellite losses, with a median fractional allelic loss (FAL) of 0.37 (range 0.12-0.69, interquartile range [IQR] 0.23-0.42), significantly different from benign PET, median FAL 0 (range 0-0.18, IQR 0-0.08, P < .0001).
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / ultrasonography. Endosonography. Loss of Heterozygosity / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Pancreas / ultrasonography. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 May;69(6):1081-4 [19410041.001]
  • (PMID = 19152901.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


76. Casadei R, Ricci C, Rega D, D'Ambra M, Pezzilli R, Tomassetti P, Campana D, Nori F, Minni F: Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas; 2010 Aug;39(6):825-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.
  • OBJECTIVE: Pancreatic endocrine tumors (PETs) are usually small, benign or low-grade malignant, and surgery should preserve the pancreatic parenchyma as much as possible.
  • METHODS: Of 82 patients having PETs, 46 with tumor less than 4 cm in diameter, without distant metastases and with R0 resection by final pathologic examination, were included in this study.
  • Enucleation was performed when the tumor did not involve the main pancreatic duct and in the absence of peripancreatic lymphadenopathy (group A); a typical resection was carried out in all other cases (group B).
  • Postoperative and long-term results were similar in the 2 groups, whereas World Health Organization classification was significantly different; enucleation was performed more frequently than typical R0 resection in benign tumors (P = 0.009).
  • CONCLUSIONS: Enucleation should be reserved for patients having benign PETs less than 4 cm in diameter and far from the main pancreatic duct.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431423.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer; 2008 Mar;15(1):343-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.
  • To analyze the genetic alterations of pheochromocytomas and evaluate the difference among malignant, extra-adrenal, and benign pheochromocytomas.
  • Forty-three tumor samples were tested for genetic changes using multiplex ligation-dependent probe amplification.
  • All 43 patients (24 women and 19 men; mean age 44.6+/-13.6 years; range 18-75 years; 9 with malignant, 7 extra-adrenal, and 27 benign) showed multiple copy number losses or gains.
  • The average copy number change was 13.10 in malignant, 13.93 in benign, and 13.47 in paraganglioma patients.
  • However, we discovered that in the malignant pheochromocytomas, 6 of the 9 patients (67%) showed erythroblastic leukemia viral oncogene homolog 2 (ERBB-2) oncogene gain, whereas only 12 of the 34 (35%) identified change in the benign and extra-adrenal pheochromocytomas.
  • Further, IHC confirmed that ERBB-2-positive staining was more frequent and stronger in malignant pheochromocytomas than in benign and extra-adrenal pheochromocytomas.
  • The results suggest that there may be certain progression of genetic events that involves chromosomes 1p, 3p, 6p, 11q, 12q, 17q, and 19q in the development of pheochromocytomas, and the activation of ERBB-2 located on chromosome 17q is an important and early event in the malignancy development of these tumor types.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Amplification. Genes, erbB-2 / genetics. Paraganglioma / genetics. Pheochromocytoma / classification. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Chromosomes, Human / genetics. Female. Genome, Human. Humans. Immunoenzyme Techniques. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):651-9 [10666394.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):453-62 [17639058.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):11-3 [11464859.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1955-60 [11994324.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1449-53 [12670888.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):707-15 [14974911.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):632-8 [1976119.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):770-4 [1346584.001]
  • [Cites] Jpn J Cancer Res. 1993 Apr;84(4):402-8 [8514606.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):531-7 [8101147.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):151-6 [7669733.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2235-49 [9811454.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):581-91 [9844631.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1872-9 [10369850.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):260-8 [15609347.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] J Pathol. 2005 Mar;205(4):514-21 [15685687.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):263-72 [15947101.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):83-93 [16215979.001]
  • [Cites] Lab Invest. 2005 Dec;85(12):1481-8 [16127456.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):509-25; ix [17548037.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):353-9 [10934139.001]
  • (PMID = 18310300.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2254511
  •  go-up   go-down


78. Nosé V, Volante M, Papotti M: Hyalinizing trabecular tumor of the thyroid: an update. Endocr Pathol; 2008;19(1):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumor of the thyroid: an update.
  • Hyalinizing trabecular tumor (HTT) is a rare thyroid tumor of follicular cell origin with a trabecular pattern of growth and marked intratrabecular hyalinization.
  • This tumor is known to share morphological and architectural similarities with paraganglioma and medullary thyroid carcinoma, as well as the nuclear features and RET/PTC1 translocations of papillary thyroid carcinoma.
  • Of great interest is the characteristic strong peripheral cytoplasmic and membranous staining of the tumor cells with MIB1 immunostain, not seen in any other thyroid neoplasm.
  • Although cases of malignant HTT have been recorded, HTT should be considered a benign neoplasm or, at most, a neoplasm of extremely low malignant potential.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Calcitonin / analysis. Cell Nucleus / pathology. Chromogranin A / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Paraganglioma / pathology. Sex Characteristics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17960500.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Ki-67 Antigen; 68238-35-7 / Keratins; 9007-12-9 / Calcitonin
  •  go-up   go-down


79. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol; 2006;17(3):225-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.
  • BACKGROUND: Several immunohistochemical markers have been used to aid in the diagnosis of follicular-derived lesions of the thyroid (FDLT).
  • In this study we analyze the diagnostic efficacy of an immunopanel of antibodies to cytokeratin-19 (CK19), galectin-3 (GAL-3), HBME-1, anti-MAP kinase (ERK), ret-oncoprotein (RET), and p16 using a tissue microarray consisting of both benign and malignant FDLT.
  • DESIGN: The study cohort consisted of 90 cases of FDLT (53 benign, 37 malignant) embedded in a microarray and immunostained with antibodies to CK19, Gal-3, HMBE-1, ERK, RET, and p16.
  • RESULTS: HMBE-1 was expressed in 70% of malignant and 10% of benign FDLT (p value: <0.0001).
  • CK19 and GAL-3 were positive in 70% and 73% of malignant lesions, respectively, and 34% of benign FDLT (p value 0.0005 and 0.0015, respectively).
  • ERK was positive in 4% of the benign and 32% of the malignant cases (p value 0.0002).
  • p16 was expressed in 2% and 46% of the benign and malignant lesions, respectively (p value 0.0001).
  • RET positivity was identified in 15% of the benign lesions and 27% of the malignant cases (p value 0.0016).
  • CONCLUSIONS: HBME-1, ERK, and p16 were more specific for malignancy, whereas CK19 and GAL-3 stained benign lesions with a higher frequency and were not specific for malignant FDLT.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308359.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Galectin 3; 0 / HBME-1 antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


80. Christ E, Wild D, Reubi JC: Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. Endocrinol Metab Clin North Am; 2010 Dec;39(4):791-800
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucagonlike peptide-1 receptors (GLP-1R) play an increasingly important role in endocrine gastrointestinal tumor management.
  • In particular, virtually all benign insulinomas express GLP-1R in high density.
  • Targeting GLP-1R by (111)In-DOTA-exendin-4 or (111)In-DPTA-exendin-4 offers a new approach that permits the successful localization of small benign insulinomas.
  • [MeSH-major] Insulinoma / genetics. Pancreatic Neoplasms / genetics. Receptors, Glucagon / physiology. Translational Medical Research
  • [MeSH-minor] Animals. Diagnostic Techniques, Endocrine. Disease Models, Animal. Gene Expression Regulation, Neoplastic / physiology. Glucagon-Like Peptide-1 Receptor. Humans. Molecular Diagnostic Techniques. Molecular Targeted Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21095545.001).
  • [ISSN] 1558-4410
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLP1R protein, human; 0 / Glucagon-Like Peptide-1 Receptor; 0 / Receptors, Glucagon
  •  go-up   go-down


81. Kyrönlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefström J, Wilson DB, Anttonen M, Heikinheimo M: GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer; 2010 Sep;17(3):709-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent cytokine that induces apoptosis in a variety of malignancies without toxic effects on benign cells.
  • [MeSH-major] Apoptosis. GATA4 Transcription Factor / metabolism. Granulosa Cell Tumor / metabolism. Granulosa Cell Tumor / pathology. Neoplasm Recurrence, Local / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Female. Granulosa Cells / metabolism. Granulosa Cells / pathology. Humans. Immunoenzyme Techniques. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20554787.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human
  •  go-up   go-down


82. Cherenko M, Slotema E, Sebag F, De Micco C, Henry JF: Mild hypercalcitoninaemia and sporadic thyroid disease. Br J Surg; 2010 May;97(5):684-90
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Not operating on patients with mild hypercalcitoninaemia (MHCT) and sporadic thyroid disease carries the risk of omitting curative surgery for medullary thyroid cancer, but systematic surgery would result in unnecessary treatment of benign pathology.
  • This study reviewed the management of MCHT and non-hereditary thyroid disease in one centre.
  • [MeSH-major] Biomarkers, Tumor / blood. Calcitonin / blood. Thyroid Diseases / diagnosis. Thyroid Gland / pathology. Thyroidectomy
  • [MeSH-minor] Carcinoma, Medullary / diagnosis. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Male. Middle Aged. Thyroid Neoplasms / diagnosis. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd.
  • (PMID = 20235084.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


83. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I, Aydin F, Knoefel WT, Stoecklein NH: Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol; 2010 Feb;162(2):391-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: EpCAM (CD326) is overexpressed in progenitor cells of endocrine pancreatic islands of Langerhans during fetal development and was suggested to act as a morphoregulatory molecule in pancreatic island ontogeny.
  • We tested whether EpCAM overexpression is reactivated in insulinomas, endocrine tumors arising in the pancreas.
  • DESIGN/METHOD: We used monoclonal anti-EpCAM antibody Ber-Ep4 for immunohistochemistry on formalin-fixed and paraffin-embedded tumor material.
  • We analyzed 53 insulinomas: 40 benign (disease stage<IIa) and 13 malignant tumors (disease stage IIIb/IV).
  • Disease stage disposition followed new TNM classification of the European Neuroendocrine Tumor Society (ENETS) for foregut neuroendocrine tumors (2006).
  • RESULTS: In 38% of the benign insulinomas (disease stage<IIa), we found strong (3+) EpCAM expression.
  • CONCLUSION: This first EpCAM expression study in benign/malignant insulinomas indicates that strong EpCAM expression could help to identify patients at risk for malignant disease and might be used as a therapeutic target for antibody-based therapies in patients with metastatic insulinoma.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20097833.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / RNA, Messenger
  •  go-up   go-down


84. Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM: Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol; 2009 Jun;218(2):232-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we demonstrated OPN and integrin alphavbeta3 expression in normal adrenal glands and benign adenomas, with staining seen exclusively in adrenocortical cells as well as even stronger staining in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Osteopontin / analysis
  • [MeSH-minor] Adenoma / chemistry. Adrenal Glands / chemistry. Blotting, Western / methods. Cell Line, Tumor. Gene Expression Profiling. Humans. Immunohistochemistry. Integrin alphaVbeta3 / analysis. Integrin alphaVbeta3 / genetics. Integrin alphaVbeta3 / metabolism. Kaplan-Meier Estimate. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transfection / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19326399.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 106441-73-0 / Osteopontin
  •  go-up   go-down


85. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M: Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer; 2009 Sep;16(3):907-18
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In other tumor entities, expression of excision repair cross complementing group 1 (ERCC1) predicts resistance to platinum compounds.
  • We have retrolectively established adrenal tissue microarrays and analyzed prospectively samples from 163 ACCs, 15 benign adrenal adenomas, and 8 normal adrenal glands by immunohistochemistry for ERCC1 protein expression.
  • ERCC1 protein was highly expressed in all normal adrenal glands, 14 benign tumors (93%) and in 75 ACCs (47%).
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / metabolism. Endonucleases / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Platinum Compounds / administration & dosage. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240185.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Platinum Compounds; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


86. Ketari-Jamoussi S, Debbiche-Chedly A, Ben Dhaou B, Boussema F, Cherif O, Cherif AR, Ben Ayed M, Bouzaine A, Rokbani L: [Giant insulinoma]. Ann Endocrinol (Paris); 2009 Mar;70(1):71-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Islet-cell tumors are the most common neuroendocrine tumors that arise from the endocrine pancreas.
  • They are typically benign and sporadic.
  • Diagnosis is generally established late because clinical signs lack specificity.
  • Imaging studies showed a voluminous tumor located between the pancreas and the spleen.
  • Histopathological examination revealed a malignant, well-differentiated neuroendocrine malignant tumor.
  • [MeSH-major] Insulinoma / pathology. Insulinoma / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937931.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 9035-68-1 / Proinsulin
  •  go-up   go-down


87. Tantau M, Pop T, Badea R, Spirchez Z, Moşteanu O, Tantau A: Intraductal ultrasonography for the assessment of preoperative biliary and pancreatic strictures. J Gastrointestin Liver Dis; 2008 Jun;17(2):217-22
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although transcutaneous ultrasonography, computer tomography and magnetic resonance greatly improved in performance, two major problems have not been completely solved yet: first, the differentiation of malignant and benign bile duct strictures, and, second, the assessment of the resectability of carcinomas underlying biliary strictures.
  • The main clinical indication for intraductal ultrasonography of the biliary tract is obstructive jaundice, which requires assessment of bile duct strictures and local tumor staging.
  • Miniprobes can contribute to the differential diagnosis of strictures localized in the main pancreatic duct, and also to localizing small endocrine tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568147.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 25
  •  go-up   go-down


88. Vilar L, Freitas Mda C, Canadas V, Albuquerque JL, Botelho CA, Egito CS, Arruda MJ, Moura e Silva L, Coelho CE, Casulari LA, Naves LA: Adrenal incidentalomas: diagnostic evaluation and long-term follow-up. Endocr Pract; 2008 Apr;14(3):269-78
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively analyzed the medical records of 52 patients with AI undergoing routine follow-up in 2 Brazilian endocrine centers.
  • During follow-up of 21 patients with nonsurgically treated AI for 6 to 36 months (mean, 24.8 +/- 8.9), no patient had tumor reduction or disappearance.
  • Moreover, evidence of cortisol hypersecretion developed after 24 months of follow-up in a 30-year-old man with a 3.5-cm adenoma in the left adrenal gland.
  • CONCLUSION: Our findings demonstrate that most AI are nonfunctioning benign lesions and emphasize the need for long-term follow-up of patients with conservatively managed lesions, in light of the potential for evolution to hormonal hypersecretion or tumor growth.
  • [MeSH-major] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Incidental Findings
  • [MeSH-minor] Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / surgery. Adrenocortical Adenoma / blood. Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / surgery. Adult. Brazil. Female. Follow-Up Studies. Humans. Hydrocortisone / blood. Longitudinal Studies. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endocr Pract. 2008 Apr;14(3):267-8 [18463031.001]
  • (PMID = 18463032.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


89. Babinska A, Sworczak K, Wisniewski P, Nałecz A, Jaskiewicz K: The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses. Exp Clin Endocrinol Diabetes; 2008 Apr;116(4):246-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The detectability of adrenal incidentalomas (incidentally found adrenal tumours) in the whole population is estimated at 0.1%; 0.42% in non-endocrine patients and at 4.3% in oncologically diagnosed ones.
  • Even up to 16% of incidentalomas of adrenal glands can be malignant lesions.
  • The issue of crucial importance is the histopathological differentiation between benign lesions and malignant tumours of the adrenal cortex and medulla.
  • OBJECTIVES: To evaluate whether the immunohistochemical analysis of the expression of p53, p21, PCNA and Ki67 in the tumour's tissue can be useful in the histopathological diagnostics of adrenal incidentalomas and whether it is important for prognosis.
  • MATERIAL AND METHODS: Our series consisted of 74 tumour samples from 164 patients operated for incidentalomas.
  • RESULTS: We found a statistically significant correlation between the expression of p53, p21, Ki67 and the differential diagnosis of adrenal cortical adenoma and adrenocortical carcinoma (for proteins: p53 p=0.010, for p21 p=0.010, for Ki67 p<0.001).
  • The statistical significant correlation between PCNA protein and diagnosis of adrenal cortical adenoma and adrenocortical carcinoma was not found.
  • The statistically significant correlation between p21, PCNA proteins and the diagnosis of benign and malignant PHEOs was not estimated.
  • There was no expression of Ki67 or p53 protein above the assumed level in benign and malignant pheochromocytomas.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology. Pheochromocytoma / pathology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / genetics. Proliferating Cell Nuclear Antigen / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Tumor Suppressor Protein p53 / genetics. p21-Activated Kinases / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393131.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


90. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


91. Boutross-Tadross O, Saleh R, Asa SL: Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol; 2007;18(3):182-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three cases considered to be benign based on histologic and cytologic criteria were negative for CK19 and HBME-1 by immunohistochemistry, and had no evidence of BRAF mutation or ret/PTC-1 and ret/PTC-3 rearrangements.
  • These results indicate that follicular variant PTC can occur in struma ovarii and that such lesions exhibit the same morphologic and immunohistochemical profile as follicular variant PTC in thyroid.
  • The application of molecular testing to verify the diagnosis can be valuable, as these lesions may harbor ret/PTC gene rearrangements.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / secondary. Ovarian Neoplasms / secondary. Struma Ovarii. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cohort Studies. DNA Mutational Analysis. Female. Humans. Keratin-19 / metabolism. Middle Aged. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058267.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Keratin-19; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


92. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer; 2007 Sep;14(3):569-85
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
  • Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour.
  • Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours.
  • Several imaging modalities have been utilised for the diagnosis and staging of these tumours.
  • The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Paraganglioma / diagnosis. Paraganglioma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chromaffin Cells / pathology. Combined Modality Therapy. Endocrine Surgical Procedures. Humans. Radiopharmaceuticals / therapeutic use. Radiotherapy / trends

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914089.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals
  • [Number-of-references] 159
  •  go-up   go-down


93. Somogyi A, Ruzicska E, Varga T, Rácz K, Nagy G: [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis]. Orv Hetil; 2007 Sep 2;148(35):1667-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECL hyper/dysplasia is known to increase the likelihood of gastric carcinoid tumor development in affected patients.
  • Results of endoscopy and biopsy showed multiple small polyps in the fundus with non-antral hypergastrinemic (type A) atrophic gastritis.
  • The histological examination indicated carcinoid tumor.
  • Non-antral, multiple polyps could cover silent neuroendocrine tumors, which are slowly growing benign endocrine tumors, however, they also might be high malignity endocrine carcinomas.
  • These tumors could be easily recognized in the clinical practice by measuring the serum or tissue chromogranin A level and other markers of tumor growth.
  • Thus screening of gastric endocrine tumors in type 1 diabetic patients with co-morbid autoimmune diseases is recommended.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoid Tumor / diagnosis. Chromogranin A / blood. Diabetes Complications / diagnosis. Diabetes Mellitus, Type 1 / complications. Hypothyroidism / complications. Stomach Neoplasms / diagnosis


94. Beuschlein F, Reincke M: Adrenocortical tumorigenesis. Ann N Y Acad Sci; 2006 Nov;1088:319-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the majority of these adrenal lesions are benign and without evidence of endocrine activity or malignancy, hormone hypersecretion needs to be ruled out by specific tests.
  • However, detection and differential diagnosis of these subtle changes in adrenal steroidogenesis can pose a diagnostic challenge to the clinician and is dependent on tests with reliable sensitivity and specificity.
  • Regulation of adrenocortical development and growth, which results in clinical symptoms if disrupted, is dependent upon the distinct spatiotemporal expression of a variety of transcription factors as well as stimulation by extra-adrenal peptide hormones.
  • Contributions to the elucidation of growth regulation of the adrenal cortex come from rare familiar syndromes associated with adrenocortical tumors, expression studies of adrenal tumor samples, in vitro studies on adrenocortical tumor cell lines, and mouse models displaying adrenal growth defects.
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / physiopathology
  • [MeSH-minor] Animals. Genes, Tumor Suppressor. Humans. Hyperaldosteronism / genetics. Hyperaldosteronism / pathology. Hyperaldosteronism / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192577.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 112
  •  go-up   go-down


95. Pradeep PV, Mishra AK, Aggarwal V, Bhargav PR, Gupta SK, Agarwal A: Adrenal cysts: an institutional experience. World J Surg; 2006 Oct;30(10):1817-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Over the past 15 years the Department of Endocrine Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, has had seven cases of adrenal cysts, of which two were functional: one patient had Cushing's syndrome and the other patient had pheochromocytoma.
  • Adrenal neoplasms, including adrenocortical carcinomas, can be associated with cysts that are benign in appearance.
  • However, surgical excision provides a definite histopathological diagnosis and also removes the fear of future complications such as hemorrhage into the cyst and local pressure effects due to the tumor.
  • CONCLUSIONS: Given that the adrenals are a vascular gland and taking into consideration the possibilities of bleeding and complications in the cyst, our treatment of choice is the elective excision of adrenal cysts.
  • [MeSH-major] Academies and Institutes / statistics & numerical data. Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Adrenalectomy / methods. Cysts / diagnosis. Cysts / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. India. Laparoscopy. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):915-7 [15711326.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):186-9 [4811049.001]
  • [Cites] J Urol. 1983 May;129(5):1031-3 [6854747.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1537-44 [15378490.001]
  • [Cites] Radiology. 1989 Oct;173(1):107-10 [2675177.001]
  • [Cites] J Endocrinol Invest. 1998 Feb;21(2):109-14 [9585385.001]
  • [Cites] Chirurgia (Bucur). 2004 Jul-Aug;99(4):255-8 [15560563.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):269-82 [6587703.001]
  • [Cites] Int Surg. 2005 Apr-Jun;90(2):78-80 [16119709.001]
  • [Cites] Ann Acad Med Singapore. 1999 Nov;28(6):863-6 [10672405.001]
  • [Cites] Am Surg. 1999 Feb;65(2):151-63 [9926751.001]
  • [Cites] Int Urol Nephrol. 1998;30(4):369-76 [9821036.001]
  • (PMID = 16983481.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Jeffery PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, Herington AC, Chopin LK: Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer; 2005 Dec;12(4):839-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we have described the expression of a human preproghrelin isoform, exon 3-deleted preproghrelin, which encodes mature ghrelin plus a novel C-terminal peptide.
  • Quantitative RT-PCR was used to demonstrate that this mRNA isoform is highly expressed in the MDA-MB-435 metastatic breast cancer cell line relative to the benign MCF-10A breast epithelial cell line.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma / metabolism. Peptide Hormones / metabolism. Peptide Hormones / pharmacology. Peptide Hormones / physiology
  • [MeSH-minor] Amino Acid Sequence. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Ghrelin. Humans. Immunohistochemistry. Molecular Sequence Data. Protein Isoforms / analysis. Protein Isoforms / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Receptors, G-Protein-Coupled / analysis. Receptors, G-Protein-Coupled / genetics. Receptors, Ghrelin. Sequence Deletion. Transcription, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322325.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ghrelin; 0 / Peptide Hormones; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Ghrelin; 0 / exon 3-deleted preproghrelin, human
  •  go-up   go-down


97. Brauckhoff M, Dralle H: [Recurrent operations on the adrenal glands]. Chirurg; 2005 Mar;76(3):227-37
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent operations on the adrenal glands].
  • Repeat adrenalectomy may be required due to ipsilateral recurrence of benign or malignant adrenal tumors after previous total or subtotal adrenalectomy.
  • Even for multivisceral resection in patients with adrenocortical carcinoma, complete resection of local recurrent tumor offers results similar to those of primary resection (5-year survival 40-60%).
  • In contrast, since no benefit on long-term survival has been shown so far by tumor debulking, palliative tumor resection should only be performed individually for control of severe endocrine symptoms.
  • In any case, during open or endoscopic approach, tumor spillage must be avoided to prevent local tumor cell implantation.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Octreotide / therapeutic use. Palliative Care. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / surgery. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1999 Mar;13(2):99-104; discussion 104-6 [10213103.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):222-4 [8561564.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Eur J Surg. 1999 May;165(5):431-5 [10391158.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] World J Surg. 2000 Jan;24(1):108-13 [10594213.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Surgery. 2003 Dec;134(6):1020-7; discussion 1027-8 [14668736.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] World J Surg. 1998 Jun;22(6):621-6; discussion 626-7 [9597938.001]
  • [Cites] N Engl J Med. 1977 Jun 2;296(22):1269-71 [859517.001]
  • [Cites] Endocr J. 2002 Apr;49(2):227-9 [12081243.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Horm Res. 2002;57(5-6):197-9 [12053093.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surg Today. 2004;34(3):251-5 [14999539.001]
  • [Cites] Surgery. 1985 Jan;97(1):16-20 [3966225.001]
  • [Cites] Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2 [11114636.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):75-110 [11159817.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Chirurg. 2003 May;74(5):473-7 [12748796.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):330-4 [2368435.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Pediatr Surg. 1993 Oct;28(10):1248-51; discussion 1251-2 [8263682.001]
  • [Cites] J Intern Med. 1995 Oct;238(4):363-7 [7595173.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1078-81 [2793991.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):535-8 [10433135.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Surgery. 1996 Dec;120(6):1064-70; discussion 1070-1 [8957496.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):39-44 [9059556.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):753-8 [1413845.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Aug;14(4):234-5 [15345163.001]
  • [Cites] J Urol. 1997 Jun;157(6):2239 [9146626.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] J Urol. 1999 Feb;161(2):395-8 [9915410.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Urol. 2000 Jul;164(1):14-7 [10840414.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):682-8; discussion 688-9 [12049539.001]
  • [Cites] World J Surg. 1982 Jul;6(4):397-402 [7123976.001]
  • [Cites] World J Surg. 1984 Aug;8(4):612-21 [6148811.001]
  • [Cites] Surgery. 1997 Dec;122(6):1068-73; discussion 1073-4 [9426421.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):664-6 [12887546.001]
  • [Cites] Horm Res. 1999;52(2):97-100 [10681640.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):344-8 [10940711.001]
  • [Cites] Minn Med. 1974 Dec;57(12):951-2 [4424014.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] J Endourol. 2002 Apr;16(3):171-4 [12028627.001]
  • [Cites] Chirurg. 1989 Apr;60(4):266-71; discussion 271-2 [2566455.001]
  • [Cites] Arch Surg. 1974 Apr;108(4):450-4 [4815920.001]
  • [Cites] Front Horm Res. 2004;31:155-62 [14674310.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]
  • [Cites] J Urol. 1998 Aug;160(2):330-4 [9679871.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Surgery. 1983 Dec;94(6):938-40 [6648808.001]
  • [Cites] Henry Ford Hosp Med J. 1987;35(2-3):127-8 [2891644.001]
  • (PMID = 15739057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35MRW7B4AD / 3-Iodobenzylguanidine; 78E4J5IB5J / Mitotane; RWM8CCW8GP / Octreotide
  • [Number-of-references] 45
  •  go-up   go-down


98. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H: Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat; 2008 Aug;110(3):465-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We examined, by immunohistochemical analysis, the expression of HIF-1alpha in normal breast tissue, benign disorders and breast cancer.
  • RESULTS: HIF-1alpha was mainly detected in tumor cell nuclei.
  • Immunoreactive nuclear HIF-1alpha was correlated with tumor size (p = 0.0013), lymph node metastasis (p = 0.0005), tumor stage (p = 0.0031) and histological grade (p = 0.0074).
  • In terms of the possible use of HIF-1alpha as a prognostic indicator, patients who had increased HIF-1alpha levels in their tumor showed shorter disease-free survival (DFS) (p < 0.0001) and overall survival (OS) (p = 0.0002) than those lacking HIF-1alpha in univariate analysis.
  • It may be useful to study the expression of HIF-1alpha using immunohistochemical analysis for better understanding of the tumor characteristics of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Diseases / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis


99. Widimský J Jr, Zelinka T, Petrák O, Strauch B, Safarík L, Kasalický M, Vranková A, Holaj R: [Diagnostic and therapeutic procedures in pheochromocytoma: current trends]. Vnitr Lek; 2007 Apr;53(4):428-33
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 24-hour monitoring of blood pressure (BP) can already contribute to the diagnosis of pheochromacytoma based on the frequent occurrence of BP variability and the absence of a night-time fall in BP.
  • 5 gene mutations have so far been identified that may be responsible for the familial form of pheochromacytoma: mutation of the von Hippel-Lindau (VHL) gene, leading to the onset of VHL syndrome, mutation of the RET-proto-oncogene in multiple endocrine adenomatosis type 2, mutation of the type 1 gene for neurofibromatosis, which is associated with von Recklinghausen's disease and finally mutation of the genes encoding the B and D subunits of succinated hydrogenase (SDHB, SDHD), which are associated with familial paragangliomas and pheochromacytoma.
  • The diagnosis of extraadrenal or multiple forms can use not only CT/MR but also imaging using the radiopharmaceutical 123I-Metaiodobenzylguanidine (MIBG) or 18F-fluorodopamine PET (only available in the USA).
  • Pharmacological treatment using alpha or beta receptor blockers with subsequent laparoscopic excision of the tumor is usually successful in benign forms of pheochromocytoma.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis
  • [MeSH-minor] Humans. Hypertension / etiology. Multiple Endocrine Neoplasia Type 2a / diagnosis. Neurofibromatosis 1 / diagnosis. Paraganglioma / diagnosis. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / etiology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578179.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 25
  •  go-up   go-down


100. Sperti C, Beltrame V, Milanetto AC, Moro M, Pedrazzoli S: Parenchyma-sparing pancreatectomies for benign or border-line tumors of the pancreas. World J Gastrointest Oncol; 2010 Jun 15;2(6):272-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchyma-sparing pancreatectomies for benign or border-line tumors of the pancreas.
  • Standard pancreatic resections, such as pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy, result in an important loss of normal pancreatic parenchyma and may cause impairment of exocrine and endocrine function.
  • Whilst these procedures are mandatory for malignant tumors, they seem to be too extensive for benign or border-line tumors, especially in patients with a long life expectancy.
  • In recent years, there has been a growing interest in parenchyma-sparing pancreatic surgery with the aim of achieving better functional results without compromising oncological radicality in patients with benign, border-line or low-grade malignant tumors.
  • Several limited resections have been introduced for isolated or multiple pancreatic lesions, depending on the location of the tumor: central pancreatectomy, duodenum-preserving pancreatic head resection with or without segmental duodenectomy, inferior head resection, dorsal pancreatectomy, excavation of the pancreatic head, middle-preserving pancreatectomy, and other multiple segmental resections.
  • Pancreatic endocrine and exocrine function is better preserved with good quality of life in most of the patients, and tumor recurrence is uncommon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160640.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999190
  • [Keywords] NOTNLM ; Limited pancreatectomy / Middle pancreatectomy / Pancreas / Pancreatectomy / Pancreatic head resection
  •  go-up   go-down






Advertisement